<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00864097</url>
  </required_header>
  <id_info>
    <org_study_id>A4091017</org_study_id>
    <secondary_id>2009-009318-41</secondary_id>
    <secondary_id>P3 6 MO OA HIP/KNEE DICLOFENAC</secondary_id>
    <nct_id>NCT00864097</nct_id>
  </id_info>
  <brief_title>Analgesic Efficacy And Safety of Tanezumab Added On To Diclofenac SR In Patients With Osteoarthritis Of The Knee Or Hip</brief_title>
  <official_title>A PHASE 3, RANDOMIZED, DOUBLE BLIND, CONTROLLED, MULTI CENTER STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF TANEZUMAB ADDED ON TO DICLOFENAC SR IN PATIENTS WITH OSTEOARTHRITIS OF THE KNEE OR HIP</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the analgesic efficacy and safety of tanezumab&#xD;
      added on to diclofenac SR in patients with osteoarthritis of the knee or hip currently&#xD;
      experiencing partial benefit from, and are tolerating, diclofenac 150 mg/day therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study was terminated on 16 Nov 2010 following a US FDA clinical hold for tanezumab&#xD;
      osteoarthritis clinical studies which halted dosing and enrollment of patients on 23 June&#xD;
      2010 for potential safety issues.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    See termination reason in detailed description.&#xD;
  </why_stopped>
  <start_date type="Actual">August 11, 2009</start_date>
  <completion_date type="Actual">November 24, 2010</completion_date>
  <primary_completion_date type="Actual">November 16, 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score at Week 16</measure>
    <time_frame>Baseline, Week 16</time_frame>
    <description>WOMAC: Self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis (OA). WOMAC pain subscale is a 5-item questionnaire used to assess the amount of pain experienced due to osteoarthritis in index knee or hip during past 48 hours. It is calculated as mean of the scores from 5 individual questions, each scored on a numerical rating scale (NRS) of 0 (no pain) to 10 (extreme pain), where higher scores indicate higher pain. Total score range for WOMAC pain subscale score is 0 (no pain) to 10 (extreme pain), where higher scores indicate higher pain.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale Score at Week 16</measure>
    <time_frame>Baseline, Week 16</time_frame>
    <description>WOMAC: Self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with OA. WOMAC physical function is a 17-item questionnaire used to assess the degree of difficulty experienced due to osteoarthritis in index knee or hip during past 48 hours. It is calculated as mean of the scores from 17 individual questions, each scored on a NRS of 0 (no difficulty) to 10 (extreme difficulty), where higher scores indicate worse function. Total score range for WOMAC physical function subscale score is 0 (no difficulty) to 10 (extreme difficulty), where higher scores indicate worse function. Physical function refers to participant's ability to move around and perform usual activities of daily living.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Patient Global Assessment (PGA) of Osteoarthritis Score at Week 16</measure>
    <time_frame>Baseline, Week 16</time_frame>
    <description>Participants answered: &quot;Considering all the ways your osteoarthritis in your index joint (knee/hip) affects you, how are you doing today?&quot; Participants responded by using a 5-point Likert scale, where 1 = very good (asymptomatic and no limitation of normal activities), 2 = good (mild symptoms and no limitation of normal activities), 3 = fair (moderate symptoms and limitation of some normal activities), 4 = poor (severe symptoms and inability to carry out most normal activities), and 5 = very poor (very severe symptoms which are intolerable and inability to carry out all normal activities). Higher score indicated worst condition.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score at Weeks 2, 4, 8, 12 and 24</measure>
    <time_frame>Baseline, Weeks 2, 4, 8, 12, and 24</time_frame>
    <description>WOMAC: Self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with OA. WOMAC pain subscale is a 5-item questionnaire used to assess the amount of pain experienced due to osteoarthritis in index knee or hip during past 48 hours. It is calculated as mean of the scores from 5 individual questions, each scored on a numerical rating scale (NRS) of 0 (no pain) to 10 (extreme pain), where higher scores indicate higher pain. Total score range for WOMAC pain subscale score is 0 (no pain) to 10 (extreme pain), where higher scores indicate higher pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale Score at Weeks 2, 4, 8, 12, and 24</measure>
    <time_frame>Baseline, Weeks 2, 4, 8, 12, and 24</time_frame>
    <description>WOMAC: Self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with OA. WOMAC physical function is a 17-item questionnaire used to assess the degree of difficulty experienced due to osteoarthritis in index knee or hip during past 48 hours. It is calculated as mean of the scores from 17 individual questions, each scored on a NRS of 0 (no difficulty) to 10 (extreme difficulty), where higher scores indicate worse function. Total score range for WOMAC physical function subscale score is 0 (no difficulty) to 10 (extreme difficulty), where higher scores indicate worse function. Physical function refers to participant's ability to move around and perform usual activities of daily living.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Patient Global Assessment (PGA) of Osteoarthritis Score at Weeks 2, 4, 8, 12, and 24</measure>
    <time_frame>Baseline, Weeks 2, 4, 8, 12, and 24</time_frame>
    <description>Participants answered: &quot;Considering all the ways your osteoarthritis in your index joint (knee/hip) affects you, how are you doing today?&quot; Participants responded by using a 5-point Likert scale, where 1 = very good (asymptomatic and no limitation of normal activities), 2 = good (mild symptoms and no limitation of normal activities), 3 = fair (moderate symptoms and limitation of some normal activities), 4 = poor (severe symptoms and inability to carry out most normal activities), and 5 = very poor (very severe symptoms which are intolerable and inability to carry out all normal activities). Higher score indicated worst condition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Outcome Measures in Rheumatology - Osteoarthritis Research Society International (OMERACT-OARSI) Response; LOCF</measure>
    <time_frame>Weeks 2, 4, 8, 12, 16, and 24</time_frame>
    <description>OMERACT-OARSI responder: participant has &gt;=50 percent (%) change and &gt;=2 absolute change from Baseline in either WOMAC pain or physical function subscale scores or at least 2 of the following being true: &gt;=20% change and &gt;=1 absolute change from Baseline in WOMAC pain subscale; &gt;=20% change and &gt;=1 absolute change from Baseline in the WOMAC physical function subscale; &gt;=20% change and &gt;=1 absolute change from Baseline in PGA of osteoarthritis. WOMAC pain and physical function score: 0 to 10 with higher score = worse response. PGA score: 1 = very good and 5 = very poor.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Cumulative Reduction From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score at Week 16 and 24</measure>
    <time_frame>Baseline, Week 16 and 24</time_frame>
    <description>WOMAC: Self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis (OA). WOMAC pain subscale is a 5-item questionnaire used to assess the amount of pain experienced due to osteoarthritis in index knee or hip during past 48 hours. It is calculated as mean of the scores from 5 individual questions, each scored on a numerical rating scale (NRS) of 0 (no pain) to 10 (extreme pain), where higher scores indicate higher pain. Total score range for WOMAC pain subscale score is 0 (no pain) to 10 (extreme pain), where higher scores indicate higher pain. Greater percentage reduction indicates greater improvement. Percentage of participants with cumulative reduction (as percent) (greater than 0%; &gt;= 10, 20, 30, 40, 50, 60, 70, 80 and 90%; = 100 %) in WOMAC pain subscale from Baseline to Weeks 16 and 24 were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With At Least 30%, 50%, 70% and 90% Reduction From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score; LOCF</measure>
    <time_frame>Baseline, Weeks 2, 4, 8, 12, 16, and 24</time_frame>
    <description>WOMAC: Self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis (OA). WOMAC pain subscale is a 5-item questionnaire used to assess the amount of pain experienced due to osteoarthritis in index knee or hip during past 48 hours. It is calculated as mean of the scores from 5 individual questions, each scored on a numerical rating scale (NRS) of 0 (no pain) to 10 (extreme pain), where higher scores indicate higher pain. Total score range for WOMAC pain subscale score is 0 (no pain) to 10 (extreme pain), where higher scores indicate higher pain. Greater percentage reduction indicates greater improvement. Percentage of participants with reduction in WOMAC pain intensity of at least (&gt;=) 30%, 50%, 70% and 90% at Weeks 2, 4, 8, 12, 16, 24 and 32 compared to baseline were classified as responders to WOMAC pain subscale and are reported here.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Improvement of at Least 2 Points in Patient Global Assessment (PGA) of Osteoarthritis; LOCF</measure>
    <time_frame>Weeks 2, 4, 8, 12, 16, and 24</time_frame>
    <description>Participants answered: &quot;Considering all the ways your osteoarthritis in your index joint (knee/hip) affects you, how are you doing today?&quot; Participants responded by using a 5-point Likert scale, where 1 = very good (asymptomatic and no limitation of normal activities), 2 = good (mild symptoms and no limitation of normal activities), 3 = fair (moderate symptoms and limitation of some normal activities), 4 = poor (severe symptoms and inability to carry out most normal activities), and 5 = very poor (very severe symptoms which are intolerable and inability to carry out all normal activities). Higher score indicated worst condition. A decrease of at least 2 points on the 5-point scale relative to baseline value indicated improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Improvement of at Least 2 Points in Patient Global Assessment (PGA) of Osteoarthritis; Baseline Observation Carried Forward (BOCF)</measure>
    <time_frame>Weeks 2, 4, 8, 12, 16, and 24</time_frame>
    <description>Participants answered: &quot;Considering all the ways your osteoarthritis in your index joint (knee/hip) affects you, how are you doing today?&quot; Participants responded by using a 5-point Likert scale, where 1 = very good (asymptomatic and no limitation of normal activities), 2 = good (mild symptoms and no limitation of normal activities), 3 = fair (moderate symptoms and limitation of some normal activities), 4 = poor (severe symptoms and inability to carry out most normal activities), and 5 = very poor (very severe symptoms which are intolerable and inability to carry out all normal activities). Higher score indicated worst condition. A decrease of at least 2 points on the 5-point scale relative to baseline value indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Average Pain Score in the Index Knee or Hip at Weeks 1, 2, 3, 4, 6, 8, 10, 12, 16, 20, and 24</measure>
    <time_frame>Baseline, Weeks 1, 2, 3, 4, 6, 8, 10, 12, 16, 20, and 24</time_frame>
    <description>Participants were asked to assess index joint (knee/hip) pain during the past 24 hours on an 0-10 point integer scale ranging from 0 (no pain) to 10 (worst possible pain). Baseline score was calculated as the mean of the scores in the index joint over the 3 days days in the initial pain assessment period and a weekly mean was calculated using the daily pain scores in the index joint within each study week. The change from Baseline was calculated using the difference between each post-baseline weekly mean and the baseline mean score, where negative change indicated an improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Stiffness Subscale Score at Weeks 2, 4, 8, 12, 16, and 24</measure>
    <time_frame>Baseline, Weeks 2, 4, 8, 12, 16, and 24</time_frame>
    <description>WOMAC: Self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with OA. WOMAC stiffness subscale is a 2-item questionnaire used to assess the amount of stiffness experienced due to osteoarthritis in index knee or hip during past 48 hours. It is calculated as mean of the scores from 2 individual questions scored on NRS of (no stiffness) to 10 (extreme stiffness), with higher scores indicate higher stiffness. Total score range for WOMAC stiffness subscale score is (no stiffness) to 10 (extreme stiffness), where higher scores indicate higher stiffness. Stiffness is defined as a sensation of decreased ease in movement of knee/hip. Negative change indicated an improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Average Score at Weeks 2, 4, 8, 12, 16, and 24</measure>
    <time_frame>Baseline, Weeks 2, 4, 8, 12, 16, and 24</time_frame>
    <description>WOMAC Index: self-administered, disease-specific 24 item questionnaire which assesses clinically important, participant-relevant symptoms for pain (5 items), stiffness (2 items), and physical function (17 items) in participants with osteoarthritis of the hip and/or knee. WOMAC average score is the mean of the WOMAC pain, physical function and stiffness subscale scores and ranges from 0 to 10, with higher score indicating worse response. Greater reduction in WOMAC average score indicated greater improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Item: Pain When Walking on a Flat Surface at Weeks 2, 4, 8, 12, 16, and 24</measure>
    <time_frame>Baseline, Week 2, 4, 8, 12, 16, 24</time_frame>
    <description>Participants answered the question: &quot;How much pain have you had when walking on a flat surface?&quot; Participants responded by using an 11-point scale where 0 = no pain and 10 = extreme pain. Where 0 is the best response and negative change indicated an improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Item: Pain When Going Up or Downstairs at Weeks 2, 4, 8, 12, 16, and 24</measure>
    <time_frame>Baseline, Weeks 2, 4, 8, 12, 16, and 24</time_frame>
    <description>Participants answered the question: &quot;How much pain have you had when going up or down the stairs?&quot; Participants responded by using an 11-point scale, where 0 = no pain and 10 = extreme pain. Where 0 is the best response and negative change indicated an improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 36-Item Short-Form Health Survey Version 2 (SF-36v2) Domain Scores at Week 12 and 24</measure>
    <time_frame>Baseline, Week 12, and 24</time_frame>
    <description>SF-36v2 was a standardized survey evaluating 8 aspects of functional health and well-being: physical and social functioning, physical and role limitations due to emotional problems, bodily pain, general health, vitality, and mental health. The total score and the score for a section was an average of the individual question scores, which were scaled 0-100. Higher scores reflected better participant status and positive change indicated an improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 36-Item Short-Form Health Survey Version 2 (SF-36v2) Physical and Mental Component Scores at Week 12 and 24</measure>
    <time_frame>Baseline, Week 12 and 24</time_frame>
    <description>SF-36v2: standardized survey evaluating 8 aspects of functional health and wellbeing (physical and social functioning, role limitations due to physical and emotional problems, bodily pain, general health, vitality, mental health). Total score for each aspect were scaled 0-100. Higher scores reflect better participant status and positive change indicated an improvement. For obtaining physical and mental component scores, z-score for each scale=(observed score - mean score for general 1990 United States [US] population)/corresponding standard deviation. The 2 component scores were obtained by multiplying each aspect z-score by physical or mental factor score coefficient (1990 general US population) and summing the eight products. Component scores indicated how many standard deviations higher (in case of positive z-score [better functioning])/lower (in case of negative z-score [worse functioning]) participant's value was relative to the mean of the reference population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in European Quality of Life - 5 Dimension (EQ-5D) Index Score at Week 24</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>EQ-5D was a standardized, participant-administered measure of health outcome. It provides a descriptive profile for 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), using 3 levels (no, moderate, or extreme dysfunction) and a single index value characterizing current health status using a visual analog scale with score ranging from 0 (worst) to 100 (best). EQ-5D summary index was obtained with a formula that weights each level of the dimensions. The index-based score was interpreted along a continuum of 0 (death) to 1 (perfect health). Negative change from baseline represented worsening.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Change From Baseline in European Quality of Life - 5 Dimension (EQ-5D) Individual Health State Profile at Week 24</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>EQ-5D was a standardized, participant-administered measure of health outcome. It provides a descriptive profile for 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), using 3 levels (no, moderate, or extreme dysfunction) and a single index value characterizing current health status using a visual analog scale with score ranging from 0 (worst) to 100 (best). Baseline EQ-5D individual health state profile was determined as number of participants &quot;no dysfunction, moderate or some dysfunction and extreme dysfunction&quot; and change from baseline in EQ-5D individual health state profile was determined as number of participants &quot;improved, no change or worsened&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Discontinued Due to Lack of Efficacy</measure>
    <time_frame>Baseline up to end of study (Week 32)</time_frame>
    <description>Number of participants who discontinued due to lack of efficacy were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Discontinuation (TTD) Due to Lack of Efficacy</measure>
    <time_frame>Baseline up to Week 16 and 24</time_frame>
    <description>Median time to discontinuation due to lack of efficacy was estimated using Kaplan-Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>Baseline up to 112 days after last intravenous dose (up to Week 32)</time_frame>
    <description>An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 112 days after last dose that were absent before treatment or that worsened relative to pretreatment state. AEs included SAEs as well as non-serious AEs which occurred during the trial.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of Participants With Intravenous Doses of Study Medication</measure>
    <time_frame>Day 1 up to Week 16</time_frame>
    <description>Number of participants were reported based on the maximum number of intravenous (IV) doses of either tanezumab or placebo received.</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">607</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Tanezumab 10 mg + diclofenac</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV tanezumab 10 mg every 8 weeks (through Week 16) and oral diclofenac SR 75 mg BID (through Week 32)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tanezumab 5 mg + diclofenac</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV tanezumab 5 mg every 8 weeks (through Week 16) and oral diclofenac SR 75 mg BID (through Week 32)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tanezumab 2.5 mg + diclofenac</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV tanezumab 2.5 mg every 8 weeks (through Week 16) and oral diclofenac SR 75 mg BID (through Week 32)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IV placebo + diclofenac</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>IV placebo to match tanezumab every 8 weeks (through Week 16) and oral diclofenac SR 75 mg BID (through Week 32)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>tanezumab</intervention_name>
    <description>IV tanezumab 10 mg every 8 weeks (through Week 16)</description>
    <arm_group_label>Tanezumab 10 mg + diclofenac</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>diclofenac</intervention_name>
    <description>Oral diclofenac SR 75 mg BID for 32 weeks</description>
    <arm_group_label>Tanezumab 10 mg + diclofenac</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>tanezumab</intervention_name>
    <description>IV tanezumab 5 mg every 8 weeks (through Week 16)</description>
    <arm_group_label>Tanezumab 5 mg + diclofenac</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>diclofenac</intervention_name>
    <description>Oral diclofenac SR 75 mg BID for 32 weeks</description>
    <arm_group_label>Tanezumab 5 mg + diclofenac</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>tanezumab</intervention_name>
    <description>IV tanezumab 2.5 mg every 8 weeks (through Week 16)</description>
    <arm_group_label>Tanezumab 2.5 mg + diclofenac</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>diclofenac</intervention_name>
    <description>Oral diclofenac SR 75 mg BID for 32 weeks</description>
    <arm_group_label>Tanezumab 2.5 mg + diclofenac</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>diclofenac</intervention_name>
    <description>Oral diclofenac SR 75 mg BID for 32 weeks</description>
    <arm_group_label>IV placebo + diclofenac</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>IV placebo</intervention_name>
    <description>IV placebo to match tanezumab every 8 weeks (through Week 16)</description>
    <arm_group_label>IV placebo + diclofenac</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Osteoarthritis of the knee or hip according to ACR criteria with Kellgren-Lawrence&#xD;
             X-ray grade equal to, or greater than, 2.&#xD;
&#xD;
          -  Patients must be experiencing some benefit from their current stable dose regimen of&#xD;
             oral diclofenac 150 mg/day and be tolerating their diclofenac regimen.&#xD;
&#xD;
          -  Pain and function levels as required by the protocol at Screening and Baseline.&#xD;
&#xD;
          -  Willing to discontinue all non-study pain medications throughout the study except as&#xD;
             permitted per protocol.&#xD;
&#xD;
          -  Willing and able to comply with lifestyle guidelines, scheduled visits, treatment&#xD;
             plan, laboratory tests and other study procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant women.&#xD;
&#xD;
          -  BMI greater than 39.&#xD;
&#xD;
          -  History of other disease that may involve index knee or hip including inflammatory&#xD;
             joint diseases, chrystalline disease (gout or pseudogout), endocrinopathies, metabolic&#xD;
             joint diseases, lupus erythematosus, rheumatoid arthritis (RA), joint infections,&#xD;
             neuropathic disorders, avascular necrosis, Paget's disease or tumors.&#xD;
&#xD;
          -  Fibromyalgia, regional pain caused by lumbar or cervical compression with&#xD;
             radiculopathy or other moderate to severe pain that may confound assessments or&#xD;
             self-evaluation of the pain associated with OA.&#xD;
&#xD;
          -  Signs and symptoms of clinically significant cardiac disease within 6 months prior to&#xD;
             screening.&#xD;
&#xD;
          -  Diagnosis or TIA within 6 months prior to screening or diagnosis of stroke with&#xD;
             residual deficits that would preclude completion of required study activities.&#xD;
&#xD;
          -  History, diagnosis , signs or symptoms of clinically significant neurological and/or&#xD;
             psychiatric disease/disorder.&#xD;
&#xD;
          -  At Screening: uncontrolled hypertension, hemoglobin A1c greater than or equal to 10%,&#xD;
             ALT or AST greater than or equal to 3X upper limit of normal, creatinine exceeding 150&#xD;
             micro-mol/L in men or 133 micro-mol/L in women.&#xD;
&#xD;
          -  Patients on warfarin or other coumadin anticoagulant therapy and/or lithium therapy&#xD;
             within 30 days prior to Screening.&#xD;
&#xD;
          -  Known hypersensitivity to NSAIDs (eg, diclofenac), cyclooxygenase inhibitors or&#xD;
             paracetamol (acetaminophen).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>LKH-Medizinische Universitatsklinik Graz</name>
      <address>
        <city>Graz</city>
        <zip>A-8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nuhr Zentrum</name>
      <address>
        <city>Senftenberg</city>
        <zip>3541</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ClinPharm International GmbH</name>
      <address>
        <city>Wien</city>
        <zip>A-1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Universitaet Wien/AKH</name>
      <address>
        <city>Wien</city>
        <zip>A-1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheuma Zentrum Favoriten</name>
      <address>
        <city>Wien</city>
        <zip>A-1100</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes</name>
      <address>
        <city>Nantes cedex 1</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Lariboisiere</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Viereck-Apotheke</name>
      <address>
        <city>Berlin-Buch</city>
        <zip>13125</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité-Universitaetsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinische Forschung Berlin-Buch GmbH</name>
      <address>
        <city>Berlin</city>
        <zip>13125</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Apotheke</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herz Apotheke</name>
      <address>
        <city>Bochum</city>
        <zip>44787</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus ClinPharm GmbH</name>
      <address>
        <city>Bochum</city>
        <zip>44787</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus ClinParm GmbH</name>
      <address>
        <city>Dresden</city>
        <zip>01067</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Apotheke im Arztehaus Mickten</name>
      <address>
        <city>Dresden</city>
        <zip>01127</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Schiller Apotheke &amp; Stadt Apotheke</name>
      <address>
        <city>Goeppingen</city>
        <zip>73033</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Schmerz- und Palliativzentrum Goeppingen</name>
      <address>
        <city>Goeppingen</city>
        <zip>73033</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Falken Apotheke Hoheluft</name>
      <address>
        <city>Hamburg</city>
        <zip>20253</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinische Forschung Hamburg GmbH</name>
      <address>
        <city>Hamburg</city>
        <zip>20253</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinische Forschung Hannover - Mitte GmbH</name>
      <address>
        <city>Hannover</city>
        <zip>30159</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loewen-Apotheke</name>
      <address>
        <city>Hannover</city>
        <zip>30159</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus ClinPharm GmbH</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arkana Apotheke OHG</name>
      <address>
        <city>Leipzig</city>
        <zip>04315</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus ClinPharm GmbH</name>
      <address>
        <city>Magdeburg</city>
        <zip>39104</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Apotheke im MSZ</name>
      <address>
        <city>Magdeburg</city>
        <zip>39112</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Apotheke des Ernst von Bergmann Klinikums</name>
      <address>
        <city>Potsdam</city>
        <zip>14467</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus ClinParm GmbH</name>
      <address>
        <city>Potsdam</city>
        <zip>14467</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kirchsteig Apotheke</name>
      <address>
        <city>Potsdam</city>
        <zip>14480</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Centrum Medyczne MEDENS S.C. Niepubliczny Zaklad</name>
      <address>
        <city>Chelm Slaski</city>
        <zip>41-403</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Malopolskie Centrum Medyczne s.c.</name>
      <address>
        <city>Krakow</city>
        <zip>31-510</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne OSTEOMED Sp. z o. o.</name>
      <address>
        <city>Warszawa</city>
        <zip>02-256</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus SCM Sp. z o.o.</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-088</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Niepubliczny Zaklad Opieki Zdrowotnej &quot;POLIMEDICA&quot;</name>
      <address>
        <city>Zgierz</city>
        <zip>95-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Hospital No. 1 &quot;Schuller&quot;</name>
      <address>
        <city>Ploiesti</city>
        <state>District Prahova</state>
        <zip>100337</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Emergency Military Hospital &quot;Dr. Carol Davila&quot;</name>
      <address>
        <city>Bucharest</city>
        <zip>010225</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duo Medical srl</name>
      <address>
        <city>Bucharest</city>
        <zip>010584</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center &quot;SANA&quot;</name>
      <address>
        <city>Bucharest</city>
        <zip>011025</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital &quot;Sf. Maria&quot;</name>
      <address>
        <city>Bucharest</city>
        <zip>011172</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center of Rheumatology &quot;Dr Ion Stoia&quot;</name>
      <address>
        <city>Bucharest</city>
        <zip>020985</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Emergency County Hospital Constanta</name>
      <address>
        <city>Constanta</city>
        <zip>900591</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>County Emergency Clinic Hospital &quot;Sf. Apostol Andrei&quot;</name>
      <address>
        <city>Galati</city>
        <zip>800578</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center polyclinic of Federal State Institution</name>
      <address>
        <city>Arkhangelsk</city>
        <zip>163000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Healthcare Institution of Moscow city &quot;City Clinical Hospital #15 n.a. O. M. Filatov&quot;</name>
      <address>
        <city>Moscow</city>
        <zip>111539</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chair of Hospital Therapy of Ryazan State Medical University</name>
      <address>
        <city>Ryazan</city>
        <zip>390026</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Petersburg State Healthcare Institution &quot;City Hospital #25 City Rheumatology Center&quot;</name>
      <address>
        <city>St. Petersburg</city>
        <zip>190068</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Educational Institution of Additional Professional Education</name>
      <address>
        <city>St. Petersburg</city>
        <zip>191015</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institution of Russian Academy of Sciences &quot;St. Petersburg Clinical Hospital of RAS&quot;</name>
      <address>
        <city>St. Petersburg</city>
        <zip>194017</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Petersburg State Healthcare Institution &quot;City Outpatient Clinical #51&quot;</name>
      <address>
        <city>St. Petersburg</city>
        <zip>196211</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Petersburg State Healthcare Institution &quot;City Pokrovskaya Hospital&quot;</name>
      <address>
        <city>St. Petersburg</city>
        <zip>199106</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Nuestra Señora de la Esperanza</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>A Coruna</state>
        <zip>15705</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Salud Petrer 1</name>
      <address>
        <city>Petrer</city>
        <state>Alicante</state>
        <zip>03610</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Basurto</name>
      <address>
        <city>Bilbao</city>
        <state>Vizcaya</state>
        <zip>48013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Comarcal de Elda</name>
      <address>
        <city>Elda Alicante</city>
        <zip>03600</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Getafe</name>
      <address>
        <city>Getafe-Madrid</city>
        <zip>28905</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital G. U. Gregorio Maranon</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario Santiago</name>
      <address>
        <city>Santiago de Compostela</city>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Me3plus AB</name>
      <address>
        <city>Goteborg</city>
        <zip>400 14</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Me3plus AB</name>
      <address>
        <city>Goteborg</city>
        <zip>412 63</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Lakemedelsstudier</name>
      <address>
        <city>Malmo</city>
        <zip>211 52</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medicinskt Centrum</name>
      <address>
        <city>Norrkoping</city>
        <zip>602 32</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chernivtsi Regional Clinical Hospital,Department of Rheumatology</name>
      <address>
        <city>Chernivtsi</city>
        <zip>58000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Road Clinical Hospital at Dnipropetrovsk station, Department of Rheumatology</name>
      <address>
        <city>Dnipropetrovsk</city>
        <zip>49008</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Urgent and Recovery Surgery named after V.K. Gusaka AMS Ukraine</name>
      <address>
        <city>Donetsk</city>
        <zip>83045</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central City Clinical Hospital#1, Department of Therapy,</name>
      <address>
        <city>Donetsk</city>
        <zip>83114</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ivano-Frankivsk Regional Clinical Hospital</name>
      <address>
        <city>Ivano-Frankivsk</city>
        <zip>76018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital #8, Department of reumatology,</name>
      <address>
        <city>Kharkiv</city>
        <zip>61176</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Institution &quot;Institute of Gerontology AMS of Ukraine&quot;</name>
      <address>
        <city>Kiev</city>
        <zip>04114</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oleksandrivska Clinical Hospital in Kyiv-Department of Rheumatology # 1</name>
      <address>
        <city>Kyiv</city>
        <zip>01023</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyiv Central Basin Clinical Hospital, Department of cardiology,</name>
      <address>
        <city>Kyiv</city>
        <zip>04053</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>4th City Communal Clinical Hospital, Department of Rheumatology,</name>
      <address>
        <city>Lviv</city>
        <zip>79011</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City communal clinical hospital #5, Dept. of Therapy, Danylo Galytskiy Lviv National Med. University</name>
      <address>
        <city>Lviv</city>
        <zip>79013</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Communal Institution Ternopil regional council, &quot;Ternopil Regional Clinical Hospital&quot;</name>
      <address>
        <city>Ternopil</city>
        <zip>46001</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vinnytsya regional clinical hospital named after M.I. Pyrogova</name>
      <address>
        <city>Vinnytsya</city>
        <zip>21018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Communal institution &quot;City Hospital #7&quot;, Department of Therapy,</name>
      <address>
        <city>Zaporizhzhia</city>
        <zip>69118</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barnsley Hospital NHS Trust</name>
      <address>
        <city>Barnsley</city>
        <state>South Yorkshire</state>
        <zip>S75 2EP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Rheumatology</name>
      <address>
        <city>Dudley, West Midlands</city>
        <zip>DY1 2HQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wrightington Hospital</name>
      <address>
        <city>Wigan</city>
        <zip>WN6 9EP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>France</country>
    <country>Germany</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A4091017&amp;StudyName=Analgesic%20Efficacy%20And%20Safety%20of%20Tanezumab%20Added%20On%20To%20Diclofenac%20SR%20In%20Patients%20With%20Osteoarthritis%20Of%20The%20Knee%20Or%20Hip</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>March 17, 2009</study_first_submitted>
  <study_first_submitted_qc>March 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2009</study_first_posted>
  <results_first_submitted>February 8, 2021</results_first_submitted>
  <results_first_submitted_qc>February 8, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 26, 2021</results_first_posted>
  <disposition_first_submitted>January 26, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>February 2, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">February 7, 2012</disposition_first_posted>
  <last_update_submitted>February 8, 2021</last_update_submitted>
  <last_update_submitted_qc>February 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Arthritis monoclonal antibody nerve growth factor (NGF) anti-NGF tanezumab PF-04383119 RN-624 OA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diclofenac</mesh_term>
    <mesh_term>Tanezumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
    <ipd_url>https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests</ipd_url>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants with osteoarthritis of knee or hip who were receiving and tolerating stable dose of diclofenac 150 milligram (mg) per day but required additional pain relief were recruited in this study.</recruitment_details>
      <pre_assignment_details>After screening, participants received study supplied diclofenac slow release (SR) 75 mg tablet twice daily for a minimum of 14 days prior to randomization.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo + Diclofenac</title>
          <description>Placebo matched to tanezumab (RN624 or PF-04383119) intravenous infusion at Baseline, Week 8 and Week 16 along with diclofenac 75 milligram (mg) slow release tablet orally twice daily up to Week 32.</description>
        </group>
        <group group_id="P2">
          <title>Tanezumab 2.5 mg + Diclofenac</title>
          <description>Tanezumab (RN624 or PF-04383119) 2.5 mg intravenous infusion at Baseline, Week 8 and Week 16 along with diclofenac 75 mg slow release tablet orally twice daily up to Week 32.</description>
        </group>
        <group group_id="P3">
          <title>Tanezumab 5 mg + Diclofenac</title>
          <description>Tanezumab (RN624 or PF-04383119) 5 mg intravenous infusion at Baseline, Week 8 and Week 16 along with diclofenac 75 mg slow release tablet orally twice daily up to Week 32.</description>
        </group>
        <group group_id="P4">
          <title>Tanezumab 10 mg + Diclofenac</title>
          <description>Tanezumab (RN624 or PF-04383119) 10 mg intravenous infusion at Baseline, Week 8 and Week 16 along with diclofenac 75 mg slow release tablet orally twice daily up to Week 32.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="154"/>
                <participants group_id="P2" count="157"/>
                <participants group_id="P3" count="151"/>
                <participants group_id="P4" count="145"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="152"/>
                <participants group_id="P2" count="157"/>
                <participants group_id="P3" count="150"/>
                <participants group_id="P4" count="145"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="19"/>
                <participants group_id="P4" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="139"/>
                <participants group_id="P2" count="137"/>
                <participants group_id="P3" count="132"/>
                <participants group_id="P4" count="125"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Terminated by sponsor</title>
              <participants_list>
                <participants group_id="P1" count="105"/>
                <participants group_id="P2" count="112"/>
                <participants group_id="P3" count="102"/>
                <participants group_id="P4" count="99"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Randomized but not treated</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intent to treat (ITT) analysis set included all randomized participants who received at least 1 dose of intravenous study medication (either tanezumab or matching placebo).</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo + Diclofenac</title>
          <description>Placebo matched to tanezumab (RN624 or PF-04383119) intravenous infusion at Baseline, Week 8 and Week 16 along with diclofenac 75 milligram (mg) slow release tablet orally twice daily up to Week 32.</description>
        </group>
        <group group_id="B2">
          <title>Tanezumab 2.5 mg + Diclofenac</title>
          <description>Tanezumab (RN624 or PF-04383119) 2.5 mg intravenous infusion at Baseline, Week 8 and Week 16 along with diclofenac 75 mg slow release tablet orally twice daily up to Week 32.</description>
        </group>
        <group group_id="B3">
          <title>Tanezumab 5 mg + Diclofenac</title>
          <description>Tanezumab (RN624 or PF-04383119) 5 mg intravenous infusion at Baseline, Week 8 and Week 16 along with diclofenac 75 mg slow release tablet orally twice daily up to Week 32.</description>
        </group>
        <group group_id="B4">
          <title>Tanezumab 10 mg + Diclofenac</title>
          <description>Tanezumab (RN624 or PF-04383119) 10 mg intravenous infusion at Baseline, Week 8 and Week 16 along with diclofenac 75 mg slow release tablet orally twice daily up to Week 32.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="152"/>
            <count group_id="B2" value="157"/>
            <count group_id="B3" value="150"/>
            <count group_id="B4" value="145"/>
            <count group_id="B5" value="604"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>18 to 44 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>45 to 64 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="84"/>
                    <measurement group_id="B2" value="86"/>
                    <measurement group_id="B3" value="88"/>
                    <measurement group_id="B4" value="78"/>
                    <measurement group_id="B5" value="336"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Greater than or equal to (&gt;=) 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="65"/>
                    <measurement group_id="B3" value="58"/>
                    <measurement group_id="B4" value="66"/>
                    <measurement group_id="B5" value="253"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="118"/>
                    <measurement group_id="B2" value="121"/>
                    <measurement group_id="B3" value="110"/>
                    <measurement group_id="B4" value="120"/>
                    <measurement group_id="B5" value="469"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="25"/>
                    <measurement group_id="B5" value="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score at Week 16</title>
        <description>WOMAC: Self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis (OA). WOMAC pain subscale is a 5-item questionnaire used to assess the amount of pain experienced due to osteoarthritis in index knee or hip during past 48 hours. It is calculated as mean of the scores from 5 individual questions, each scored on a numerical rating scale (NRS) of 0 (no pain) to 10 (extreme pain), where higher scores indicate higher pain. Total score range for WOMAC pain subscale score is 0 (no pain) to 10 (extreme pain), where higher scores indicate higher pain.</description>
        <time_frame>Baseline, Week 16</time_frame>
        <population>Intent to treat (ITT) analysis set included all randomized participants who received at least 1 dose of intravenous study medication (either tanezumab or matching placebo). Here 'overall number of participants analyzed' signifies participants evaluable for this measure. Last observation carried forward (LOCF) method was used to impute missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + Diclofenac</title>
            <description>Placebo matched to tanezumab (RN624 or PF-04383119) intravenous infusion at Baseline, Week 8 and Week 16 along with diclofenac 75 milligram (mg) slow release tablet orally twice daily up to Week 32.</description>
          </group>
          <group group_id="O2">
            <title>Tanezumab 2.5 mg + Diclofenac</title>
            <description>Tanezumab (RN624 or PF-04383119) 2.5 mg intravenous infusion at Baseline, Week 8 and Week 16 along with diclofenac 75 mg slow release tablet orally twice daily up to Week 32.</description>
          </group>
          <group group_id="O3">
            <title>Tanezumab 5 mg + Diclofenac</title>
            <description>Tanezumab (RN624 or PF-04383119) 5 mg intravenous infusion at Baseline, Week 8 and Week 16 along with diclofenac 75 mg slow release tablet orally twice daily up to Week 32.</description>
          </group>
          <group group_id="O4">
            <title>Tanezumab 10 mg + Diclofenac</title>
            <description>Tanezumab (RN624 or PF-04383119) 10 mg intravenous infusion at Baseline, Week 8 and Week 16 along with diclofenac 75 mg slow release tablet orally twice daily up to Week 32.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score at Week 16</title>
          <description>WOMAC: Self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis (OA). WOMAC pain subscale is a 5-item questionnaire used to assess the amount of pain experienced due to osteoarthritis in index knee or hip during past 48 hours. It is calculated as mean of the scores from 5 individual questions, each scored on a numerical rating scale (NRS) of 0 (no pain) to 10 (extreme pain), where higher scores indicate higher pain. Total score range for WOMAC pain subscale score is 0 (no pain) to 10 (extreme pain), where higher scores indicate higher pain.</description>
          <population>Intent to treat (ITT) analysis set included all randomized participants who received at least 1 dose of intravenous study medication (either tanezumab or matching placebo). Here 'overall number of participants analyzed' signifies participants evaluable for this measure. Last observation carried forward (LOCF) method was used to impute missing values.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="156"/>
                <count group_id="O3" value="150"/>
                <count group_id="O4" value="145"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.06" spread="1.23"/>
                    <measurement group_id="O2" value="5.78" spread="1.36"/>
                    <measurement group_id="O3" value="5.76" spread="1.32"/>
                    <measurement group_id="O4" value="5.87" spread="1.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.91" spread="1.90"/>
                    <measurement group_id="O2" value="-2.18" spread="1.90"/>
                    <measurement group_id="O3" value="-2.28" spread="1.99"/>
                    <measurement group_id="O4" value="-2.42" spread="2.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>LS means were estimated from the corresponding analysis of covariance (ANCOVA) model. The ANCOVA model included treatment as main effect, baseline value, and index joint as covariates and study site as random effect.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.039</p_value>
            <method>ANCOVA</method>
            <param_type>Least Squares (LS) Mean Difference</param_type>
            <param_value>-0.42</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.20</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.81</ci_lower_limit>
            <ci_upper_limit>-0.02</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>LS means were estimated from the corresponding ANCOVA model. The ANCOVA model included treatment as main effect, baseline value, and index joint as covariates and study site as random effect.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.011</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.52</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.20</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.91</ci_lower_limit>
            <ci_upper_limit>-0.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>LS means were estimated from the corresponding ANCOVA model. The ANCOVA model included treatment as main effect, baseline value, and index joint as covariates and study site as random effect.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.005</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.57</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.20</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.97</ci_lower_limit>
            <ci_upper_limit>-0.17</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale Score at Week 16</title>
        <description>WOMAC: Self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with OA. WOMAC physical function is a 17-item questionnaire used to assess the degree of difficulty experienced due to osteoarthritis in index knee or hip during past 48 hours. It is calculated as mean of the scores from 17 individual questions, each scored on a NRS of 0 (no difficulty) to 10 (extreme difficulty), where higher scores indicate worse function. Total score range for WOMAC physical function subscale score is 0 (no difficulty) to 10 (extreme difficulty), where higher scores indicate worse function. Physical function refers to participant's ability to move around and perform usual activities of daily living.</description>
        <time_frame>Baseline, Week 16</time_frame>
        <population>ITT analysis set included all randomized participants who received at least 1 dose of intravenous study medication (either tanezumab or matching placebo). Here 'overall number of participants analyzed' signifies participants evaluable for this measure. LOCF method was used to impute missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + Diclofenac</title>
            <description>Placebo matched to tanezumab (RN624 or PF-04383119) intravenous infusion at Baseline, Week 8 and Week 16 along with diclofenac 75 milligram (mg) slow release tablet orally twice daily up to Week 32.</description>
          </group>
          <group group_id="O2">
            <title>Tanezumab 2.5 mg + Diclofenac</title>
            <description>Tanezumab (RN624 or PF-04383119) 2.5 mg intravenous infusion at Baseline, Week 8 and Week 16 along with diclofenac 75 mg slow release tablet orally twice daily up to Week 32.</description>
          </group>
          <group group_id="O3">
            <title>Tanezumab 5 mg + Diclofenac</title>
            <description>Tanezumab (RN624 or PF-04383119) 5 mg intravenous infusion at Baseline, Week 8 and Week 16 along with diclofenac 75 mg slow release tablet orally twice daily up to Week 32.</description>
          </group>
          <group group_id="O4">
            <title>Tanezumab 10 mg + Diclofenac</title>
            <description>Tanezumab (RN624 or PF-04383119) 10 mg intravenous infusion at Baseline, Week 8 and Week 16 along with diclofenac 75 mg slow release tablet orally twice daily up to Week 32.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale Score at Week 16</title>
          <description>WOMAC: Self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with OA. WOMAC physical function is a 17-item questionnaire used to assess the degree of difficulty experienced due to osteoarthritis in index knee or hip during past 48 hours. It is calculated as mean of the scores from 17 individual questions, each scored on a NRS of 0 (no difficulty) to 10 (extreme difficulty), where higher scores indicate worse function. Total score range for WOMAC physical function subscale score is 0 (no difficulty) to 10 (extreme difficulty), where higher scores indicate worse function. Physical function refers to participant's ability to move around and perform usual activities of daily living.</description>
          <population>ITT analysis set included all randomized participants who received at least 1 dose of intravenous study medication (either tanezumab or matching placebo). Here 'overall number of participants analyzed' signifies participants evaluable for this measure. LOCF method was used to impute missing values.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="157"/>
                <count group_id="O3" value="150"/>
                <count group_id="O4" value="145"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.24" spread="1.45"/>
                    <measurement group_id="O2" value="5.86" spread="1.51"/>
                    <measurement group_id="O3" value="5.90" spread="1.22"/>
                    <measurement group_id="O4" value="5.91" spread="1.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.76" spread="1.78"/>
                    <measurement group_id="O2" value="-2.11" spread="1.99"/>
                    <measurement group_id="O3" value="-2.23" spread="1.99"/>
                    <measurement group_id="O4" value="-2.35" spread="2.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>LS means were estimated from the corresponding ANCOVA model. The ANCOVA model included treatment as main effect, baseline value, and index joint as covariates and study site as random effect.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.010</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.51</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.20</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.91</ci_lower_limit>
            <ci_upper_limit>-0.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>LS means were estimated from the corresponding ANCOVA model. The ANCOVA model included treatment as main effect, baseline value, and index joint as covariates and study site as random effect.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.63</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.20</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.03</ci_lower_limit>
            <ci_upper_limit>-0.23</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>LS means were estimated from the corresponding ANCOVA model. The ANCOVA model included treatment as main effect, baseline value, and index joint as covariates and study site as random effect.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.70</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.20</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.10</ci_lower_limit>
            <ci_upper_limit>-0.30</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Patient Global Assessment (PGA) of Osteoarthritis Score at Week 16</title>
        <description>Participants answered: &quot;Considering all the ways your osteoarthritis in your index joint (knee/hip) affects you, how are you doing today?&quot; Participants responded by using a 5-point Likert scale, where 1 = very good (asymptomatic and no limitation of normal activities), 2 = good (mild symptoms and no limitation of normal activities), 3 = fair (moderate symptoms and limitation of some normal activities), 4 = poor (severe symptoms and inability to carry out most normal activities), and 5 = very poor (very severe symptoms which are intolerable and inability to carry out all normal activities). Higher score indicated worst condition.</description>
        <time_frame>Baseline, Week 16</time_frame>
        <population>ITT analysis set included all randomized participants who received at least 1 dose of intravenous study medication (either tanezumab or matching placebo). Here 'overall number of participants analyzed' signifies participants evaluable for this measure. LOCF method was used to impute missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + Diclofenac</title>
            <description>Placebo matched to tanezumab (RN624 or PF-04383119) intravenous infusion at Baseline, Week 8 and Week 16 along with diclofenac 75 milligram (mg) slow release tablet orally twice daily up to Week 32.</description>
          </group>
          <group group_id="O2">
            <title>Tanezumab 2.5 mg + Diclofenac</title>
            <description>Tanezumab (RN624 or PF-04383119) 2.5 mg intravenous infusion at Baseline, Week 8 and Week 16 along with diclofenac 75 mg slow release tablet orally twice daily up to Week 32.</description>
          </group>
          <group group_id="O3">
            <title>Tanezumab 5 mg + Diclofenac</title>
            <description>Tanezumab (RN624 or PF-04383119) 5 mg intravenous infusion at Baseline, Week 8 and Week 16 along with diclofenac 75 mg slow release tablet orally twice daily up to Week 32.</description>
          </group>
          <group group_id="O4">
            <title>Tanezumab 10 mg + Diclofenac</title>
            <description>Tanezumab (RN624 or PF-04383119) 10 mg intravenous infusion at Baseline, Week 8 and Week 16 along with diclofenac 75 mg slow release tablet orally twice daily up to Week 32.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Patient Global Assessment (PGA) of Osteoarthritis Score at Week 16</title>
          <description>Participants answered: &quot;Considering all the ways your osteoarthritis in your index joint (knee/hip) affects you, how are you doing today?&quot; Participants responded by using a 5-point Likert scale, where 1 = very good (asymptomatic and no limitation of normal activities), 2 = good (mild symptoms and no limitation of normal activities), 3 = fair (moderate symptoms and limitation of some normal activities), 4 = poor (severe symptoms and inability to carry out most normal activities), and 5 = very poor (very severe symptoms which are intolerable and inability to carry out all normal activities). Higher score indicated worst condition.</description>
          <population>ITT analysis set included all randomized participants who received at least 1 dose of intravenous study medication (either tanezumab or matching placebo). Here 'overall number of participants analyzed' signifies participants evaluable for this measure. LOCF method was used to impute missing values.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="156"/>
                <count group_id="O3" value="150"/>
                <count group_id="O4" value="145"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.39" spread="0.57"/>
                    <measurement group_id="O2" value="3.28" spread="0.46"/>
                    <measurement group_id="O3" value="3.43" spread="0.56"/>
                    <measurement group_id="O4" value="3.37" spread="0.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.41" spread="0.70"/>
                    <measurement group_id="O2" value="-0.49" spread="0.74"/>
                    <measurement group_id="O3" value="-0.61" spread="0.83"/>
                    <measurement group_id="O4" value="-0.63" spread="0.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>LS means were estimated from the corresponding ANCOVA model. The ANCOVA model included treatment as main effect, baseline value, and index joint as covariates and study site as random effect.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.022</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.17</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.08</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.32</ci_lower_limit>
            <ci_upper_limit>-0.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>LS means were estimated from the corresponding ANCOVA model. The ANCOVA model included treatment as main effect, baseline value, and index joint as covariates and study site as random effect.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.020</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.18</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.08</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.33</ci_lower_limit>
            <ci_upper_limit>-0.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>LS means were estimated from the corresponding ANCOVA model. The ANCOVA model included treatment as main effect, baseline value, and index joint as covariates and study site as random effect.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.24</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.08</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.40</ci_lower_limit>
            <ci_upper_limit>-0.09</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score at Weeks 2, 4, 8, 12 and 24</title>
        <description>WOMAC: Self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with OA. WOMAC pain subscale is a 5-item questionnaire used to assess the amount of pain experienced due to osteoarthritis in index knee or hip during past 48 hours. It is calculated as mean of the scores from 5 individual questions, each scored on a numerical rating scale (NRS) of 0 (no pain) to 10 (extreme pain), where higher scores indicate higher pain. Total score range for WOMAC pain subscale score is 0 (no pain) to 10 (extreme pain), where higher scores indicate higher pain.</description>
        <time_frame>Baseline, Weeks 2, 4, 8, 12, and 24</time_frame>
        <population>ITT analysis set included all randomized participants who received at least 1 dose of intravenous study medication (either tanezumab or matching placebo). Here 'overall number of participants analyzed' signifies participants evaluable for this measure. LOCF method was used to impute missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + Diclofenac</title>
            <description>Placebo matched to tanezumab (RN624 or PF-04383119) intravenous infusion at Baseline, Week 8 and Week 16 along with diclofenac 75 milligram (mg) slow release tablet orally twice daily up to Week 32.</description>
          </group>
          <group group_id="O2">
            <title>Tanezumab 2.5 mg + Diclofenac</title>
            <description>Tanezumab (RN624 or PF-04383119) 2.5 mg intravenous infusion at Baseline, Week 8 and Week 16 along with diclofenac 75 mg slow release tablet orally twice daily up to Week 32.</description>
          </group>
          <group group_id="O3">
            <title>Tanezumab 5 mg + Diclofenac</title>
            <description>Tanezumab (RN624 or PF-04383119) 5 mg intravenous infusion at Baseline, Week 8 and Week 16 along with diclofenac 75 mg slow release tablet orally twice daily up to Week 32.</description>
          </group>
          <group group_id="O4">
            <title>Tanezumab 10 mg + Diclofenac</title>
            <description>Tanezumab (RN624 or PF-04383119) 10 mg intravenous infusion at Baseline, Week 8 and Week 16 along with diclofenac 75 mg slow release tablet orally twice daily up to Week 32.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score at Weeks 2, 4, 8, 12 and 24</title>
          <description>WOMAC: Self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with OA. WOMAC pain subscale is a 5-item questionnaire used to assess the amount of pain experienced due to osteoarthritis in index knee or hip during past 48 hours. It is calculated as mean of the scores from 5 individual questions, each scored on a numerical rating scale (NRS) of 0 (no pain) to 10 (extreme pain), where higher scores indicate higher pain. Total score range for WOMAC pain subscale score is 0 (no pain) to 10 (extreme pain), where higher scores indicate higher pain.</description>
          <population>ITT analysis set included all randomized participants who received at least 1 dose of intravenous study medication (either tanezumab or matching placebo). Here 'overall number of participants analyzed' signifies participants evaluable for this measure. LOCF method was used to impute missing values.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="156"/>
                <count group_id="O3" value="150"/>
                <count group_id="O4" value="145"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.30" spread="1.43"/>
                    <measurement group_id="O2" value="-1.22" spread="1.52"/>
                    <measurement group_id="O3" value="-1.21" spread="1.67"/>
                    <measurement group_id="O4" value="-0.86" spread="1.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.51" spread="1.55"/>
                    <measurement group_id="O2" value="-1.76" spread="1.65"/>
                    <measurement group_id="O3" value="-2.12" spread="1.70"/>
                    <measurement group_id="O4" value="-1.93" spread="1.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.63" spread="1.54"/>
                    <measurement group_id="O2" value="-1.88" spread="1.68"/>
                    <measurement group_id="O3" value="-2.22" spread="1.92"/>
                    <measurement group_id="O4" value="-2.34" spread="1.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.81" spread="1.59"/>
                    <measurement group_id="O2" value="-2.23" spread="1.82"/>
                    <measurement group_id="O3" value="-2.50" spread="2.03"/>
                    <measurement group_id="O4" value="-2.42" spread="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.81" spread="1.91"/>
                    <measurement group_id="O2" value="-2.11" spread="2.08"/>
                    <measurement group_id="O3" value="-2.24" spread="2.23"/>
                    <measurement group_id="O4" value="-2.19" spread="2.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>At Week 2: LS means were estimated from the corresponding ANCOVA model. The ANCOVA model included treatment as main effect, baseline value, and index joint as covariates and study site as random effect.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.957</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.01</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.17</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.32</ci_lower_limit>
            <ci_upper_limit>0.34</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>At Week 2: LS means were estimated from the corresponding ANCOVA model. The ANCOVA model included treatment as main effect, baseline value, and index joint as covariates and study site as random effect.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.899</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.02</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.17</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.31</ci_lower_limit>
            <ci_upper_limit>0.35</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>At Week 2: LS means were estimated from the corresponding ANCOVA model. The ANCOVA model included treatment as main effect, baseline value, and index joint as covariates and study site as random effect.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.022</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.39</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.17</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.06</ci_lower_limit>
            <ci_upper_limit>0.72</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>At Week 4: LS means were estimated from the corresponding ANCOVA model. The ANCOVA model included treatment as main effect, baseline value, and index joint as covariates and study site as random effect.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.052</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.35</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.18</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.70</ci_lower_limit>
            <ci_upper_limit>0.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>At Week 4: LS means were estimated from the corresponding ANCOVA model. The ANCOVA model included treatment as main effect, baseline value, and index joint as covariates and study site as random effect.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.69</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.18</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.05</ci_lower_limit>
            <ci_upper_limit>-0.34</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>At Week 4: LS means were estimated from the corresponding ANCOVA model. The ANCOVA model included treatment as main effect, baseline value, and index joint as covariates and study site as random effect.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.008</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.48</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.18</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.84</ci_lower_limit>
            <ci_upper_limit>-0.13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>At Week 8: LS means were estimated from the corresponding ANCOVA model. The ANCOVA model included treatment as main effect, baseline value, and index joint as covariates and study site as random effect.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.058</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.35</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.19</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.72</ci_lower_limit>
            <ci_upper_limit>0.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>At Week 8: LS means were estimated from the corresponding ANCOVA model. The ANCOVA model included treatment as main effect, baseline value, and index joint as covariates and study site as random effect.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.69</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.19</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.05</ci_lower_limit>
            <ci_upper_limit>-0.32</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>At Week 8: LS means were estimated from the corresponding ANCOVA model. The ANCOVA model included treatment as main effect, baseline value, and index joint as covariates and study site as random effect.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.75</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.19</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.12</ci_lower_limit>
            <ci_upper_limit>-0.38</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>At Week 12: LS means were estimated from the corresponding ANCOVA model. The ANCOVA model included treatment as main effect, baseline value, and index joint as covariates and study site as random effect.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.007</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.53</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.19</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.91</ci_lower_limit>
            <ci_upper_limit>-0.15</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>At Week 12: LS means were estimated from the corresponding ANCOVA model. The ANCOVA model included treatment as main effect, baseline value, and index joint as covariates and study site as random effect.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.80</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.20</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.18</ci_lower_limit>
            <ci_upper_limit>-0.41</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>At Week 12: LS means were estimated from the corresponding ANCOVA model. The ANCOVA model included treatment as main effect, baseline value, and index joint as covariates and study site as random effect.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.66</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.20</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.05</ci_lower_limit>
            <ci_upper_limit>-0.28</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale Score at Weeks 2, 4, 8, 12, and 24</title>
        <description>WOMAC: Self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with OA. WOMAC physical function is a 17-item questionnaire used to assess the degree of difficulty experienced due to osteoarthritis in index knee or hip during past 48 hours. It is calculated as mean of the scores from 17 individual questions, each scored on a NRS of 0 (no difficulty) to 10 (extreme difficulty), where higher scores indicate worse function. Total score range for WOMAC physical function subscale score is 0 (no difficulty) to 10 (extreme difficulty), where higher scores indicate worse function. Physical function refers to participant's ability to move around and perform usual activities of daily living.</description>
        <time_frame>Baseline, Weeks 2, 4, 8, 12, and 24</time_frame>
        <population>ITT analysis set included all randomized participants who received at least 1 dose of intravenous study medication (either tanezumab or matching placebo). Here 'overall number of participants analyzed' signifies participants evaluable for this measure. LOCF method was used to impute missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + Diclofenac</title>
            <description>Placebo matched to tanezumab (RN624 or PF-04383119) intravenous infusion at Baseline, Week 8 and Week 16 along with diclofenac 75 milligram (mg) slow release tablet orally twice daily up to Week 32.</description>
          </group>
          <group group_id="O2">
            <title>Tanezumab 2.5 mg + Diclofenac</title>
            <description>Tanezumab (RN624 or PF-04383119) 2.5 mg intravenous infusion at Baseline, Week 8 and Week 16 along with diclofenac 75 mg slow release tablet orally twice daily up to Week 32.</description>
          </group>
          <group group_id="O3">
            <title>Tanezumab 5 mg + Diclofenac</title>
            <description>Tanezumab (RN624 or PF-04383119) 5 mg intravenous infusion at Baseline, Week 8 and Week 16 along with diclofenac 75 mg slow release tablet orally twice daily up to Week 32.</description>
          </group>
          <group group_id="O4">
            <title>Tanezumab 10 mg + Diclofenac</title>
            <description>Tanezumab (RN624 or PF-04383119) 10 mg intravenous infusion at Baseline, Week 8 and Week 16 along with diclofenac 75 mg slow release tablet orally twice daily up to Week 32.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale Score at Weeks 2, 4, 8, 12, and 24</title>
          <description>WOMAC: Self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with OA. WOMAC physical function is a 17-item questionnaire used to assess the degree of difficulty experienced due to osteoarthritis in index knee or hip during past 48 hours. It is calculated as mean of the scores from 17 individual questions, each scored on a NRS of 0 (no difficulty) to 10 (extreme difficulty), where higher scores indicate worse function. Total score range for WOMAC physical function subscale score is 0 (no difficulty) to 10 (extreme difficulty), where higher scores indicate worse function. Physical function refers to participant's ability to move around and perform usual activities of daily living.</description>
          <population>ITT analysis set included all randomized participants who received at least 1 dose of intravenous study medication (either tanezumab or matching placebo). Here 'overall number of participants analyzed' signifies participants evaluable for this measure. LOCF method was used to impute missing values.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="156"/>
                <count group_id="O3" value="150"/>
                <count group_id="O4" value="145"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.31" spread="1.42"/>
                    <measurement group_id="O2" value="-1.18" spread="1.45"/>
                    <measurement group_id="O3" value="-1.30" spread="1.57"/>
                    <measurement group_id="O4" value="-1.06" spread="1.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.46" spread="1.49"/>
                    <measurement group_id="O2" value="-1.58" spread="1.71"/>
                    <measurement group_id="O3" value="-2.09" spread="1.84"/>
                    <measurement group_id="O4" value="-1.81" spread="1.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.59" spread="1.52"/>
                    <measurement group_id="O2" value="-1.76" spread="1.72"/>
                    <measurement group_id="O3" value="-2.22" spread="1.88"/>
                    <measurement group_id="O4" value="-2.13" spread="1.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.75" spread="1.60"/>
                    <measurement group_id="O2" value="-2.13" spread="1.87"/>
                    <measurement group_id="O3" value="-2.43" spread="2.01"/>
                    <measurement group_id="O4" value="-2.28" spread="1.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.70" spread="1.86"/>
                    <measurement group_id="O2" value="-1.99" spread="2.13"/>
                    <measurement group_id="O3" value="-2.17" spread="2.19"/>
                    <measurement group_id="O4" value="-2.08" spread="2.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>At Week 2: LS means were estimated from the corresponding ANCOVA model. The ANCOVA model included treatment as main effect, baseline value, and index joint as covariates and study site as random effect.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.754</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.05</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.15</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.25</ci_lower_limit>
            <ci_upper_limit>0.35</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>At Week 2: LS means were estimated from the corresponding ANCOVA model. The ANCOVA model included treatment as main effect, baseline value, and index joint as covariates and study site as random effect.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.706</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.06</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.16</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.36</ci_lower_limit>
            <ci_upper_limit>0.25</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>At Week 2: LS means were estimated from the corresponding ANCOVA model. The ANCOVA model included treatment as main effect, baseline value, and index joint as covariates and study site as random effect.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.266</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.17</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.16</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.13</ci_lower_limit>
            <ci_upper_limit>0.48</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>At Week 4: LS means were estimated from the corresponding ANCOVA model. The ANCOVA model included treatment as main effect, baseline value, and index joint as covariates and study site as random effect.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.195</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.23</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.18</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.58</ci_lower_limit>
            <ci_upper_limit>0.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>At Week 4: LS means were estimated from the corresponding ANCOVA model. The ANCOVA model included treatment as main effect, baseline value, and index joint as covariates and study site as random effect.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.72</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.18</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.07</ci_lower_limit>
            <ci_upper_limit>-0.36</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>At Week 4: LS means were estimated from the corresponding ANCOVA model. The ANCOVA model included treatment as main effect, baseline value, and index joint as covariates and study site as random effect.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.019</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.43</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.18</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.78</ci_lower_limit>
            <ci_upper_limit>-0.07</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>At Week 8: LS means were estimated from the corresponding ANCOVA model. The ANCOVA model included treatment as main effect, baseline value, and index joint as covariates and study site as random effect.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.126</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.28</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.18</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.64</ci_lower_limit>
            <ci_upper_limit>0.08</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>At Week 8: LS means were estimated from the corresponding ANCOVA model. The ANCOVA model included treatment as main effect, baseline value, and index joint as covariates and study site as random effect.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.73</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.19</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.10</ci_lower_limit>
            <ci_upper_limit>-0.37</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>At Week 8: LS means were estimated from the corresponding ANCOVA model. The ANCOVA model included treatment as main effect, baseline value, and index joint as covariates and study site as random effect.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.62</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.19</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.98</ci_lower_limit>
            <ci_upper_limit>-0.25</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>At Week 12: LS means were estimated from the corresponding ANCOVA model. The ANCOVA model included treatment as main effect, baseline value, and index joint as covariates and study site as random effect.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.007</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.52</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.19</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.90</ci_lower_limit>
            <ci_upper_limit>-0.15</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>At Week 12: LS means were estimated from the corresponding ANCOVA model. The ANCOVA model included treatment as main effect, baseline value, and index joint as covariates and study site as random effect.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.82</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.19</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.21</ci_lower_limit>
            <ci_upper_limit>-0.44</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>At Week 12: LS means were estimated from the corresponding ANCOVA model. The ANCOVA model included treatment as main effect, baseline value, and index joint as covariates and study site as random effect.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.64</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.20</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.02</ci_lower_limit>
            <ci_upper_limit>-0.25</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Patient Global Assessment (PGA) of Osteoarthritis Score at Weeks 2, 4, 8, 12, and 24</title>
        <description>Participants answered: &quot;Considering all the ways your osteoarthritis in your index joint (knee/hip) affects you, how are you doing today?&quot; Participants responded by using a 5-point Likert scale, where 1 = very good (asymptomatic and no limitation of normal activities), 2 = good (mild symptoms and no limitation of normal activities), 3 = fair (moderate symptoms and limitation of some normal activities), 4 = poor (severe symptoms and inability to carry out most normal activities), and 5 = very poor (very severe symptoms which are intolerable and inability to carry out all normal activities). Higher score indicated worst condition.</description>
        <time_frame>Baseline, Weeks 2, 4, 8, 12, and 24</time_frame>
        <population>ITT analysis set included all randomized participants who received at least 1 dose of intravenous study medication (either tanezumab or matching placebo). Here 'overall number of participants analyzed' signifies participants evaluable for this measure. LOCF method was used to impute missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + Diclofenac</title>
            <description>Placebo matched to tanezumab (RN624 or PF-04383119) intravenous infusion at Baseline, Week 8 and Week 16 along with diclofenac 75 milligram (mg) slow release tablet orally twice daily up to Week 32.</description>
          </group>
          <group group_id="O2">
            <title>Tanezumab 2.5 mg + Diclofenac</title>
            <description>Tanezumab (RN624 or PF-04383119) 2.5 mg intravenous infusion at Baseline, Week 8 and Week 16 along with diclofenac 75 mg slow release tablet orally twice daily up to Week 32.</description>
          </group>
          <group group_id="O3">
            <title>Tanezumab 5 mg + Diclofenac</title>
            <description>Tanezumab (RN624 or PF-04383119) 5 mg intravenous infusion at Baseline, Week 8 and Week 16 along with diclofenac 75 mg slow release tablet orally twice daily up to Week 32.</description>
          </group>
          <group group_id="O4">
            <title>Tanezumab 10 mg + Diclofenac</title>
            <description>Tanezumab (RN624 or PF-04383119) 10 mg intravenous infusion at Baseline, Week 8 and Week 16 along with diclofenac 75 mg slow release tablet orally twice daily up to Week 32.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Patient Global Assessment (PGA) of Osteoarthritis Score at Weeks 2, 4, 8, 12, and 24</title>
          <description>Participants answered: &quot;Considering all the ways your osteoarthritis in your index joint (knee/hip) affects you, how are you doing today?&quot; Participants responded by using a 5-point Likert scale, where 1 = very good (asymptomatic and no limitation of normal activities), 2 = good (mild symptoms and no limitation of normal activities), 3 = fair (moderate symptoms and limitation of some normal activities), 4 = poor (severe symptoms and inability to carry out most normal activities), and 5 = very poor (very severe symptoms which are intolerable and inability to carry out all normal activities). Higher score indicated worst condition.</description>
          <population>ITT analysis set included all randomized participants who received at least 1 dose of intravenous study medication (either tanezumab or matching placebo). Here 'overall number of participants analyzed' signifies participants evaluable for this measure. LOCF method was used to impute missing values.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="156"/>
                <count group_id="O3" value="150"/>
                <count group_id="O4" value="145"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.36" spread="0.79"/>
                    <measurement group_id="O2" value="-0.37" spread="0.65"/>
                    <measurement group_id="O3" value="-0.40" spread="0.68"/>
                    <measurement group_id="O4" value="-0.28" spread="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.40" spread="0.74"/>
                    <measurement group_id="O2" value="-0.45" spread="0.63"/>
                    <measurement group_id="O3" value="-0.65" spread="0.82"/>
                    <measurement group_id="O4" value="-0.54" spread="0.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.37" spread="0.72"/>
                    <measurement group_id="O2" value="-0.44" spread="0.70"/>
                    <measurement group_id="O3" value="-0.71" spread="0.85"/>
                    <measurement group_id="O4" value="-0.66" spread="0.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.45" spread="0.80"/>
                    <measurement group_id="O2" value="-0.52" spread="0.71"/>
                    <measurement group_id="O3" value="-0.69" spread="0.78"/>
                    <measurement group_id="O4" value="-0.61" spread="0.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.45" spread="0.77"/>
                    <measurement group_id="O2" value="-0.46" spread="0.76"/>
                    <measurement group_id="O3" value="-0.57" spread="0.86"/>
                    <measurement group_id="O4" value="-0.57" spread="0.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>At Week 2: LS means were estimated from the corresponding ANCOVA model. The ANCOVA model included treatment as main effect, baseline value, and index joint as covariates and study site as random effect.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.200</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.09</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.07</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.22</ci_lower_limit>
            <ci_upper_limit>0.05</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>At Week 2: LS means were estimated from the corresponding ANCOVA model. The ANCOVA model included treatment as main effect, baseline value, and index joint as covariates and study site as random effect.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.754</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.02</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.07</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.15</ci_lower_limit>
            <ci_upper_limit>0.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>At Week 2: LS means were estimated from the corresponding ANCOVA model. The ANCOVA model included treatment as main effect, baseline value, and index joint as covariates and study site as random effect.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.449</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.05</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.07</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.08</ci_lower_limit>
            <ci_upper_limit>0.18</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>At Week 4: LS means were estimated from the corresponding ANCOVA model. The ANCOVA model included treatment as main effect, baseline value, and index joint as covariates and study site as random effect.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.062</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.13</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.07</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.27</ci_lower_limit>
            <ci_upper_limit>0.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>At Week 4: LS means were estimated from the corresponding ANCOVA model. The ANCOVA model included treatment as main effect, baseline value, and index joint as covariates and study site as random effect.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.22</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.07</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.36</ci_lower_limit>
            <ci_upper_limit>-0.08</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>At Week 4: LS means were estimated from the corresponding ANCOVA model. The ANCOVA model included treatment as main effect, baseline value, and index joint as covariates and study site as random effect.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.026</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.16</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.07</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.30</ci_lower_limit>
            <ci_upper_limit>-0.02</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>At Week 8: LS means were estimated from the corresponding ANCOVA model. The ANCOVA model included treatment as main effect, baseline value, and index joint as covariates and study site as random effect.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.032</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.16</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.07</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.31</ci_lower_limit>
            <ci_upper_limit>-0.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>At Week 8: LS means were estimated from the corresponding ANCOVA model. The ANCOVA model included treatment as main effect, baseline value, and index joint as covariates and study site as random effect.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.33</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.07</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.48</ci_lower_limit>
            <ci_upper_limit>-0.19</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>At Week 8: LS means were estimated from the corresponding ANCOVA model. The ANCOVA model included treatment as main effect, baseline value, and index joint as covariates and study site as random effect.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.31</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.08</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.45</ci_lower_limit>
            <ci_upper_limit>-0.16</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>At Week 12: LS means were estimated from the corresponding ANCOVA model. The ANCOVA model included treatment as main effect, baseline value, and index joint as covariates and study site as random effect.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.038</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.15</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.07</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.30</ci_lower_limit>
            <ci_upper_limit>-0.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>At Week 12: LS means were estimated from the corresponding ANCOVA model. The ANCOVA model included treatment as main effect, baseline value, and index joint as covariates and study site as random effect.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.22</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.07</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.37</ci_lower_limit>
            <ci_upper_limit>-0.07</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>At Week 12: LS means were estimated from the corresponding ANCOVA model. The ANCOVA model included treatment as main effect, baseline value, and index joint as covariates and study site as random effect.</groups_desc>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.016</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.18</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.08</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.33</ci_lower_limit>
            <ci_upper_limit>-0.03</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Outcome Measures in Rheumatology - Osteoarthritis Research Society International (OMERACT-OARSI) Response; LOCF</title>
        <description>OMERACT-OARSI responder: participant has &gt;=50 percent (%) change and &gt;=2 absolute change from Baseline in either WOMAC pain or physical function subscale scores or at least 2 of the following being true: &gt;=20% change and &gt;=1 absolute change from Baseline in WOMAC pain subscale; &gt;=20% change and &gt;=1 absolute change from Baseline in the WOMAC physical function subscale; &gt;=20% change and &gt;=1 absolute change from Baseline in PGA of osteoarthritis. WOMAC pain and physical function score: 0 to 10 with higher score = worse response. PGA score: 1 = very good and 5 = very poor.</description>
        <time_frame>Weeks 2, 4, 8, 12, 16, and 24</time_frame>
        <population>ITT analysis set included all randomized participants who received at least 1 dose of intravenous study medication (either tanezumab or matching placebo). Here 'overall number of participants analyzed' signifies participants evaluable for this measure. LOCF method was used to impute missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + Diclofenac</title>
            <description>Placebo matched to tanezumab (RN624 or PF-04383119) intravenous infusion at Baseline, Week 8 and Week 16 along with diclofenac 75 milligram (mg) slow release tablet orally twice daily up to Week 32.</description>
          </group>
          <group group_id="O2">
            <title>Tanezumab 2.5 mg + Diclofenac</title>
            <description>Tanezumab (RN624 or PF-04383119) 2.5 mg intravenous infusion at Baseline, Week 8 and Week 16 along with diclofenac 75 mg slow release tablet orally twice daily up to Week 32.</description>
          </group>
          <group group_id="O3">
            <title>Tanezumab 5 mg + Diclofenac</title>
            <description>Tanezumab (RN624 or PF-04383119) 5 mg intravenous infusion at Baseline, Week 8 and Week 16 along with diclofenac 75 mg slow release tablet orally twice daily up to Week 32.</description>
          </group>
          <group group_id="O4">
            <title>Tanezumab 10 mg + Diclofenac</title>
            <description>Tanezumab (RN624 or PF-04383119) 10 mg intravenous infusion at Baseline, Week 8 and Week 16 along with diclofenac 75 mg slow release tablet orally twice daily up to Week 32.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Outcome Measures in Rheumatology - Osteoarthritis Research Society International (OMERACT-OARSI) Response; LOCF</title>
          <description>OMERACT-OARSI responder: participant has &gt;=50 percent (%) change and &gt;=2 absolute change from Baseline in either WOMAC pain or physical function subscale scores or at least 2 of the following being true: &gt;=20% change and &gt;=1 absolute change from Baseline in WOMAC pain subscale; &gt;=20% change and &gt;=1 absolute change from Baseline in the WOMAC physical function subscale; &gt;=20% change and &gt;=1 absolute change from Baseline in PGA of osteoarthritis. WOMAC pain and physical function score: 0 to 10 with higher score = worse response. PGA score: 1 = very good and 5 = very poor.</description>
          <population>ITT analysis set included all randomized participants who received at least 1 dose of intravenous study medication (either tanezumab or matching placebo). Here 'overall number of participants analyzed' signifies participants evaluable for this measure. LOCF method was used to impute missing values.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="156"/>
                <count group_id="O3" value="150"/>
                <count group_id="O4" value="145"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.7"/>
                    <measurement group_id="O2" value="37.2"/>
                    <measurement group_id="O3" value="43.3"/>
                    <measurement group_id="O4" value="34.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.3"/>
                    <measurement group_id="O2" value="57.1"/>
                    <measurement group_id="O3" value="65.3"/>
                    <measurement group_id="O4" value="59.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.2"/>
                    <measurement group_id="O2" value="58.3"/>
                    <measurement group_id="O3" value="68.0"/>
                    <measurement group_id="O4" value="69.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.5"/>
                    <measurement group_id="O2" value="67.3"/>
                    <measurement group_id="O3" value="73.3"/>
                    <measurement group_id="O4" value="73.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.9"/>
                    <measurement group_id="O2" value="66.7"/>
                    <measurement group_id="O3" value="66.7"/>
                    <measurement group_id="O4" value="72.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.3"/>
                    <measurement group_id="O2" value="65.4"/>
                    <measurement group_id="O3" value="64.7"/>
                    <measurement group_id="O4" value="67.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Cumulative Reduction From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score at Week 16 and 24</title>
        <description>WOMAC: Self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis (OA). WOMAC pain subscale is a 5-item questionnaire used to assess the amount of pain experienced due to osteoarthritis in index knee or hip during past 48 hours. It is calculated as mean of the scores from 5 individual questions, each scored on a numerical rating scale (NRS) of 0 (no pain) to 10 (extreme pain), where higher scores indicate higher pain. Total score range for WOMAC pain subscale score is 0 (no pain) to 10 (extreme pain), where higher scores indicate higher pain. Greater percentage reduction indicates greater improvement. Percentage of participants with cumulative reduction (as percent) (greater than 0%; &gt;= 10, 20, 30, 40, 50, 60, 70, 80 and 90%; = 100 %) in WOMAC pain subscale from Baseline to Weeks 16 and 24 were reported.</description>
        <time_frame>Baseline, Week 16 and 24</time_frame>
        <population>ITT analysis set included all randomized participants who received at least 1 dose of intravenous study medication (either tanezumab or matching placebo). Here ' overall number of participants analyzed' signifies participants evaluable for this measure. LOCF method was used to impute missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + Diclofenac</title>
            <description>Placebo matched to tanezumab (RN624 or PF-04383119) intravenous infusion at Baseline, Week 8 and Week 16 along with diclofenac 75 milligram (mg) slow release tablet orally twice daily up to Week 32.</description>
          </group>
          <group group_id="O2">
            <title>Tanezumab 2.5 mg + Diclofenac</title>
            <description>Tanezumab (RN624 or PF-04383119) 2.5 mg intravenous infusion at Baseline, Week 8 and Week 16 along with diclofenac 75 mg slow release tablet orally twice daily up to Week 32.</description>
          </group>
          <group group_id="O3">
            <title>Tanezumab 5 mg + Diclofenac</title>
            <description>Tanezumab (RN624 or PF-04383119) 5 mg intravenous infusion at Baseline, Week 8 and Week 16 along with diclofenac 75 mg slow release tablet orally twice daily up to Week 32.</description>
          </group>
          <group group_id="O4">
            <title>Tanezumab 10 mg + Diclofenac</title>
            <description>Tanezumab (RN624 or PF-04383119) 10 mg intravenous infusion at Baseline, Week 8 and Week 16 along with diclofenac 75 mg slow release tablet orally twice daily up to Week 32.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Cumulative Reduction From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score at Week 16 and 24</title>
          <description>WOMAC: Self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis (OA). WOMAC pain subscale is a 5-item questionnaire used to assess the amount of pain experienced due to osteoarthritis in index knee or hip during past 48 hours. It is calculated as mean of the scores from 5 individual questions, each scored on a numerical rating scale (NRS) of 0 (no pain) to 10 (extreme pain), where higher scores indicate higher pain. Total score range for WOMAC pain subscale score is 0 (no pain) to 10 (extreme pain), where higher scores indicate higher pain. Greater percentage reduction indicates greater improvement. Percentage of participants with cumulative reduction (as percent) (greater than 0%; &gt;= 10, 20, 30, 40, 50, 60, 70, 80 and 90%; = 100 %) in WOMAC pain subscale from Baseline to Weeks 16 and 24 were reported.</description>
          <population>ITT analysis set included all randomized participants who received at least 1 dose of intravenous study medication (either tanezumab or matching placebo). Here ' overall number of participants analyzed' signifies participants evaluable for this measure. LOCF method was used to impute missing values.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="156"/>
                <count group_id="O3" value="150"/>
                <count group_id="O4" value="145"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 16: Greater than 0% reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.2"/>
                    <measurement group_id="O2" value="88.5"/>
                    <measurement group_id="O3" value="88.7"/>
                    <measurement group_id="O4" value="84.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: &gt;=10% reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.7"/>
                    <measurement group_id="O2" value="82.7"/>
                    <measurement group_id="O3" value="76.7"/>
                    <measurement group_id="O4" value="77.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: &gt;=20% reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.8"/>
                    <measurement group_id="O2" value="69.9"/>
                    <measurement group_id="O3" value="68.7"/>
                    <measurement group_id="O4" value="75.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: &gt;=30% reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0"/>
                    <measurement group_id="O2" value="54.5"/>
                    <measurement group_id="O3" value="61.3"/>
                    <measurement group_id="O4" value="66.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: &gt;=40% reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.8"/>
                    <measurement group_id="O2" value="48.7"/>
                    <measurement group_id="O3" value="50.7"/>
                    <measurement group_id="O4" value="60.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: &gt;=50% reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.9"/>
                    <measurement group_id="O2" value="35.9"/>
                    <measurement group_id="O3" value="40.0"/>
                    <measurement group_id="O4" value="49.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: &gt;=60% reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.7"/>
                    <measurement group_id="O2" value="26.3"/>
                    <measurement group_id="O3" value="28.7"/>
                    <measurement group_id="O4" value="31.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: &gt;=70% reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.2"/>
                    <measurement group_id="O2" value="17.3"/>
                    <measurement group_id="O3" value="20.0"/>
                    <measurement group_id="O4" value="19.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: &gt;=80% reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.9"/>
                    <measurement group_id="O2" value="9.0"/>
                    <measurement group_id="O3" value="10.7"/>
                    <measurement group_id="O4" value="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: &gt;=90% reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0"/>
                    <measurement group_id="O2" value="5.8"/>
                    <measurement group_id="O3" value="6.7"/>
                    <measurement group_id="O4" value="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: 100% reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7"/>
                    <measurement group_id="O2" value="2.6"/>
                    <measurement group_id="O3" value="2.0"/>
                    <measurement group_id="O4" value="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24: Greater than 0% reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.6"/>
                    <measurement group_id="O2" value="82.7"/>
                    <measurement group_id="O3" value="82.0"/>
                    <measurement group_id="O4" value="84.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24: &gt;=10% reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.4"/>
                    <measurement group_id="O2" value="76.9"/>
                    <measurement group_id="O3" value="74.7"/>
                    <measurement group_id="O4" value="75.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24: &gt;=20% reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.5"/>
                    <measurement group_id="O2" value="67.3"/>
                    <measurement group_id="O3" value="65.3"/>
                    <measurement group_id="O4" value="69.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24: &gt;=30% reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.0"/>
                    <measurement group_id="O2" value="58.3"/>
                    <measurement group_id="O3" value="59.3"/>
                    <measurement group_id="O4" value="59.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24: &gt;=40% reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.5"/>
                    <measurement group_id="O2" value="47.4"/>
                    <measurement group_id="O3" value="47.3"/>
                    <measurement group_id="O4" value="51.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24: &gt;=50% reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.3"/>
                    <measurement group_id="O2" value="38.5"/>
                    <measurement group_id="O3" value="40.0"/>
                    <measurement group_id="O4" value="42.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24: &gt;=60% reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.4"/>
                    <measurement group_id="O2" value="26.3"/>
                    <measurement group_id="O3" value="34.0"/>
                    <measurement group_id="O4" value="31.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24: &gt;=70% reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5"/>
                    <measurement group_id="O2" value="18.6"/>
                    <measurement group_id="O3" value="22.7"/>
                    <measurement group_id="O4" value="21.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24: &gt;=80% reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6"/>
                    <measurement group_id="O2" value="11.5"/>
                    <measurement group_id="O3" value="14.7"/>
                    <measurement group_id="O4" value="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24: &gt;=90% reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9"/>
                    <measurement group_id="O2" value="8.3"/>
                    <measurement group_id="O3" value="8.0"/>
                    <measurement group_id="O4" value="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24: 100% reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7"/>
                    <measurement group_id="O2" value="3.8"/>
                    <measurement group_id="O3" value="3.3"/>
                    <measurement group_id="O4" value="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With At Least 30%, 50%, 70% and 90% Reduction From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score; LOCF</title>
        <description>WOMAC: Self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis (OA). WOMAC pain subscale is a 5-item questionnaire used to assess the amount of pain experienced due to osteoarthritis in index knee or hip during past 48 hours. It is calculated as mean of the scores from 5 individual questions, each scored on a numerical rating scale (NRS) of 0 (no pain) to 10 (extreme pain), where higher scores indicate higher pain. Total score range for WOMAC pain subscale score is 0 (no pain) to 10 (extreme pain), where higher scores indicate higher pain. Greater percentage reduction indicates greater improvement. Percentage of participants with reduction in WOMAC pain intensity of at least (&gt;=) 30%, 50%, 70% and 90% at Weeks 2, 4, 8, 12, 16, 24 and 32 compared to baseline were classified as responders to WOMAC pain subscale and are reported here.</description>
        <time_frame>Baseline, Weeks 2, 4, 8, 12, 16, and 24</time_frame>
        <population>ITT analysis set included all randomized participants who received at least 1 dose of intravenous study medication (either tanezumab or matching placebo). Here 'overall number of participants analyzed' signifies participants evaluable for this measure. LOCF method was used to impute missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + Diclofenac</title>
            <description>Placebo matched to tanezumab (RN624 or PF-04383119) intravenous infusion at Baseline, Week 8 and Week 16 along with diclofenac 75 milligram (mg) slow release tablet orally twice daily up to Week 32.</description>
          </group>
          <group group_id="O2">
            <title>Tanezumab 2.5 mg + Diclofenac</title>
            <description>Tanezumab (RN624 or PF-04383119) 2.5 mg intravenous infusion at Baseline, Week 8 and Week 16 along with diclofenac 75 mg slow release tablet orally twice daily up to Week 32.</description>
          </group>
          <group group_id="O3">
            <title>Tanezumab 5 mg + Diclofenac</title>
            <description>Tanezumab (RN624 or PF-04383119) 5 mg intravenous infusion at Baseline, Week 8 and Week 16 along with diclofenac 75 mg slow release tablet orally twice daily up to Week 32.</description>
          </group>
          <group group_id="O4">
            <title>Tanezumab 10 mg + Diclofenac</title>
            <description>Tanezumab (RN624 or PF-04383119) 10 mg intravenous infusion at Baseline, Week 8 and Week 16 along with diclofenac 75 mg slow release tablet orally twice daily up to Week 32.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With At Least 30%, 50%, 70% and 90% Reduction From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score; LOCF</title>
          <description>WOMAC: Self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis (OA). WOMAC pain subscale is a 5-item questionnaire used to assess the amount of pain experienced due to osteoarthritis in index knee or hip during past 48 hours. It is calculated as mean of the scores from 5 individual questions, each scored on a numerical rating scale (NRS) of 0 (no pain) to 10 (extreme pain), where higher scores indicate higher pain. Total score range for WOMAC pain subscale score is 0 (no pain) to 10 (extreme pain), where higher scores indicate higher pain. Greater percentage reduction indicates greater improvement. Percentage of participants with reduction in WOMAC pain intensity of at least (&gt;=) 30%, 50%, 70% and 90% at Weeks 2, 4, 8, 12, 16, 24 and 32 compared to baseline were classified as responders to WOMAC pain subscale and are reported here.</description>
          <population>ITT analysis set included all randomized participants who received at least 1 dose of intravenous study medication (either tanezumab or matching placebo). Here 'overall number of participants analyzed' signifies participants evaluable for this measure. LOCF method was used to impute missing values.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="156"/>
                <count group_id="O3" value="150"/>
                <count group_id="O4" value="145"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2: At least 30% reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.3"/>
                    <measurement group_id="O2" value="28.8"/>
                    <measurement group_id="O3" value="32.0"/>
                    <measurement group_id="O4" value="24.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: At least 50% reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.8"/>
                    <measurement group_id="O2" value="16.0"/>
                    <measurement group_id="O3" value="16.7"/>
                    <measurement group_id="O4" value="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: At least 70% reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6"/>
                    <measurement group_id="O2" value="6.4"/>
                    <measurement group_id="O3" value="7.3"/>
                    <measurement group_id="O4" value="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2: At least 90% reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0"/>
                    <measurement group_id="O2" value="1.3"/>
                    <measurement group_id="O3" value="1.3"/>
                    <measurement group_id="O4" value="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: At least 30% reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.1"/>
                    <measurement group_id="O2" value="51.9"/>
                    <measurement group_id="O3" value="57.3"/>
                    <measurement group_id="O4" value="50.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: At least 50% reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.1"/>
                    <measurement group_id="O2" value="26.9"/>
                    <measurement group_id="O3" value="34.0"/>
                    <measurement group_id="O4" value="30.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: At least 70% reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.9"/>
                    <measurement group_id="O2" value="10.3"/>
                    <measurement group_id="O3" value="12.7"/>
                    <measurement group_id="O4" value="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4: At least 90% reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0"/>
                    <measurement group_id="O2" value="1.9"/>
                    <measurement group_id="O3" value="6.0"/>
                    <measurement group_id="O4" value="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: At least 30% reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.4"/>
                    <measurement group_id="O2" value="51.9"/>
                    <measurement group_id="O3" value="57.3"/>
                    <measurement group_id="O4" value="63.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: At least 50% reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0"/>
                    <measurement group_id="O2" value="27.6"/>
                    <measurement group_id="O3" value="38.0"/>
                    <measurement group_id="O4" value="38.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: At least 70% reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9"/>
                    <measurement group_id="O2" value="9.6"/>
                    <measurement group_id="O3" value="17.3"/>
                    <measurement group_id="O4" value="19.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8: At least 90% reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0"/>
                    <measurement group_id="O2" value="5.1"/>
                    <measurement group_id="O3" value="4.7"/>
                    <measurement group_id="O4" value="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: At least 30% reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.7"/>
                    <measurement group_id="O2" value="57.1"/>
                    <measurement group_id="O3" value="64.0"/>
                    <measurement group_id="O4" value="63.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: At least 50% reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.0"/>
                    <measurement group_id="O2" value="36.5"/>
                    <measurement group_id="O3" value="46.7"/>
                    <measurement group_id="O4" value="42.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: At least 70% reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2"/>
                    <measurement group_id="O2" value="16.7"/>
                    <measurement group_id="O3" value="24.0"/>
                    <measurement group_id="O4" value="24.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12: At least 90% reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0"/>
                    <measurement group_id="O2" value="6.4"/>
                    <measurement group_id="O3" value="8.7"/>
                    <measurement group_id="O4" value="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: At least 30% reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0"/>
                    <measurement group_id="O2" value="54.5"/>
                    <measurement group_id="O3" value="61.3"/>
                    <measurement group_id="O4" value="66.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: At least 50% reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.9"/>
                    <measurement group_id="O2" value="35.9"/>
                    <measurement group_id="O3" value="40.0"/>
                    <measurement group_id="O4" value="49.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: At least 70% reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.2"/>
                    <measurement group_id="O2" value="17.3"/>
                    <measurement group_id="O3" value="20.0"/>
                    <measurement group_id="O4" value="19.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16: At least 90% reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0"/>
                    <measurement group_id="O2" value="5.8"/>
                    <measurement group_id="O3" value="6.7"/>
                    <measurement group_id="O4" value="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24: At least 30% reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.0"/>
                    <measurement group_id="O2" value="58.3"/>
                    <measurement group_id="O3" value="59.3"/>
                    <measurement group_id="O4" value="59.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24: At least 50% reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.3"/>
                    <measurement group_id="O2" value="38.5"/>
                    <measurement group_id="O3" value="40.0"/>
                    <measurement group_id="O4" value="42.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24: At least 70% reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5"/>
                    <measurement group_id="O2" value="18.6"/>
                    <measurement group_id="O3" value="22.7"/>
                    <measurement group_id="O4" value="21.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24: At least 90% reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9"/>
                    <measurement group_id="O2" value="8.3"/>
                    <measurement group_id="O3" value="8.0"/>
                    <measurement group_id="O4" value="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Improvement of at Least 2 Points in Patient Global Assessment (PGA) of Osteoarthritis; LOCF</title>
        <description>Participants answered: &quot;Considering all the ways your osteoarthritis in your index joint (knee/hip) affects you, how are you doing today?&quot; Participants responded by using a 5-point Likert scale, where 1 = very good (asymptomatic and no limitation of normal activities), 2 = good (mild symptoms and no limitation of normal activities), 3 = fair (moderate symptoms and limitation of some normal activities), 4 = poor (severe symptoms and inability to carry out most normal activities), and 5 = very poor (very severe symptoms which are intolerable and inability to carry out all normal activities). Higher score indicated worst condition. A decrease of at least 2 points on the 5-point scale relative to baseline value indicated improvement.</description>
        <time_frame>Weeks 2, 4, 8, 12, 16, and 24</time_frame>
        <population>ITT analysis set included all randomized participants who received at least 1 dose of intravenous study medication (either tanezumab or matching placebo). Here 'overall number of participants analyzed' signifies participants evaluable for this measure. LOCF method was used to impute missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + Diclofenac</title>
            <description>Placebo matched to tanezumab (RN624 or PF-04383119) intravenous infusion at Baseline, Week 8 and Week 16 along with diclofenac 75 milligram (mg) slow release tablet orally twice daily up to Week 32.</description>
          </group>
          <group group_id="O2">
            <title>Tanezumab 2.5 mg + Diclofenac</title>
            <description>Tanezumab (RN624 or PF-04383119) 2.5 mg intravenous infusion at Baseline, Week 8 and Week 16 along with diclofenac 75 mg slow release tablet orally twice daily up to Week 32.</description>
          </group>
          <group group_id="O3">
            <title>Tanezumab 5 mg + Diclofenac</title>
            <description>Tanezumab (RN624 or PF-04383119) 5 mg intravenous infusion at Baseline, Week 8 and Week 16 along with diclofenac 75 mg slow release tablet orally twice daily up to Week 32.</description>
          </group>
          <group group_id="O4">
            <title>Tanezumab 10 mg + Diclofenac</title>
            <description>Tanezumab (RN624 or PF-04383119) 10 mg intravenous infusion at Baseline, Week 8 and Week 16 along with diclofenac 75 mg slow release tablet orally twice daily up to Week 32.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Improvement of at Least 2 Points in Patient Global Assessment (PGA) of Osteoarthritis; LOCF</title>
          <description>Participants answered: &quot;Considering all the ways your osteoarthritis in your index joint (knee/hip) affects you, how are you doing today?&quot; Participants responded by using a 5-point Likert scale, where 1 = very good (asymptomatic and no limitation of normal activities), 2 = good (mild symptoms and no limitation of normal activities), 3 = fair (moderate symptoms and limitation of some normal activities), 4 = poor (severe symptoms and inability to carry out most normal activities), and 5 = very poor (very severe symptoms which are intolerable and inability to carry out all normal activities). Higher score indicated worst condition. A decrease of at least 2 points on the 5-point scale relative to baseline value indicated improvement.</description>
          <population>ITT analysis set included all randomized participants who received at least 1 dose of intravenous study medication (either tanezumab or matching placebo). Here 'overall number of participants analyzed' signifies participants evaluable for this measure. LOCF method was used to impute missing values.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="156"/>
                <count group_id="O3" value="150"/>
                <count group_id="O4" value="145"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.9"/>
                    <measurement group_id="O2" value="5.8"/>
                    <measurement group_id="O3" value="4.7"/>
                    <measurement group_id="O4" value="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6"/>
                    <measurement group_id="O2" value="3.2"/>
                    <measurement group_id="O3" value="14.7"/>
                    <measurement group_id="O4" value="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3"/>
                    <measurement group_id="O2" value="6.4"/>
                    <measurement group_id="O3" value="18.0"/>
                    <measurement group_id="O4" value="14.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6"/>
                    <measurement group_id="O2" value="6.4"/>
                    <measurement group_id="O3" value="14.0"/>
                    <measurement group_id="O4" value="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6"/>
                    <measurement group_id="O2" value="5.8"/>
                    <measurement group_id="O3" value="14.7"/>
                    <measurement group_id="O4" value="16.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.9"/>
                    <measurement group_id="O2" value="5.8"/>
                    <measurement group_id="O3" value="12.7"/>
                    <measurement group_id="O4" value="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Improvement of at Least 2 Points in Patient Global Assessment (PGA) of Osteoarthritis; Baseline Observation Carried Forward (BOCF)</title>
        <description>Participants answered: &quot;Considering all the ways your osteoarthritis in your index joint (knee/hip) affects you, how are you doing today?&quot; Participants responded by using a 5-point Likert scale, where 1 = very good (asymptomatic and no limitation of normal activities), 2 = good (mild symptoms and no limitation of normal activities), 3 = fair (moderate symptoms and limitation of some normal activities), 4 = poor (severe symptoms and inability to carry out most normal activities), and 5 = very poor (very severe symptoms which are intolerable and inability to carry out all normal activities). Higher score indicated worst condition. A decrease of at least 2 points on the 5-point scale relative to baseline value indicates improvement.</description>
        <time_frame>Weeks 2, 4, 8, 12, 16, and 24</time_frame>
        <population>ITT analysis set included all randomized participants who received at least 1 dose of intravenous study medication (either tanezumab or matching placebo). Here 'overall number of participants analyzed' signifies participants evaluable for this measure. BOCF method was used to impute missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + Diclofenac</title>
            <description>Placebo matched to tanezumab (RN624 or PF-04383119) intravenous infusion at Baseline, Week 8 and Week 16 along with diclofenac 75 milligram (mg) slow release tablet orally twice daily up to Week 32.</description>
          </group>
          <group group_id="O2">
            <title>Tanezumab 2.5 mg + Diclofenac</title>
            <description>Tanezumab (RN624 or PF-04383119) 2.5 mg intravenous infusion at Baseline, Week 8 and Week 16 along with diclofenac 75 mg slow release tablet orally twice daily up to Week 32.</description>
          </group>
          <group group_id="O3">
            <title>Tanezumab 5 mg + Diclofenac</title>
            <description>Tanezumab (RN624 or PF-04383119) 5 mg intravenous infusion at Baseline, Week 8 and Week 16 along with diclofenac 75 mg slow release tablet orally twice daily up to Week 32.</description>
          </group>
          <group group_id="O4">
            <title>Tanezumab 10 mg + Diclofenac</title>
            <description>Tanezumab (RN624 or PF-04383119) 10 mg intravenous infusion at Baseline, Week 8 and Week 16 along with diclofenac 75 mg slow release tablet orally twice daily up to Week 32.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Improvement of at Least 2 Points in Patient Global Assessment (PGA) of Osteoarthritis; Baseline Observation Carried Forward (BOCF)</title>
          <description>Participants answered: &quot;Considering all the ways your osteoarthritis in your index joint (knee/hip) affects you, how are you doing today?&quot; Participants responded by using a 5-point Likert scale, where 1 = very good (asymptomatic and no limitation of normal activities), 2 = good (mild symptoms and no limitation of normal activities), 3 = fair (moderate symptoms and limitation of some normal activities), 4 = poor (severe symptoms and inability to carry out most normal activities), and 5 = very poor (very severe symptoms which are intolerable and inability to carry out all normal activities). Higher score indicated worst condition. A decrease of at least 2 points on the 5-point scale relative to baseline value indicates improvement.</description>
          <population>ITT analysis set included all randomized participants who received at least 1 dose of intravenous study medication (either tanezumab or matching placebo). Here 'overall number of participants analyzed' signifies participants evaluable for this measure. BOCF method was used to impute missing values.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="156"/>
                <count group_id="O3" value="150"/>
                <count group_id="O4" value="145"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.9"/>
                    <measurement group_id="O2" value="5.8"/>
                    <measurement group_id="O3" value="4.7"/>
                    <measurement group_id="O4" value="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6"/>
                    <measurement group_id="O2" value="3.2"/>
                    <measurement group_id="O3" value="14.7"/>
                    <measurement group_id="O4" value="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3"/>
                    <measurement group_id="O2" value="6.4"/>
                    <measurement group_id="O3" value="17.3"/>
                    <measurement group_id="O4" value="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6"/>
                    <measurement group_id="O2" value="6.4"/>
                    <measurement group_id="O3" value="13.3"/>
                    <measurement group_id="O4" value="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6"/>
                    <measurement group_id="O2" value="5.8"/>
                    <measurement group_id="O3" value="14.0"/>
                    <measurement group_id="O4" value="14.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3"/>
                    <measurement group_id="O2" value="4.5"/>
                    <measurement group_id="O3" value="10.0"/>
                    <measurement group_id="O4" value="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Average Pain Score in the Index Knee or Hip at Weeks 1, 2, 3, 4, 6, 8, 10, 12, 16, 20, and 24</title>
        <description>Participants were asked to assess index joint (knee/hip) pain during the past 24 hours on an 0-10 point integer scale ranging from 0 (no pain) to 10 (worst possible pain). Baseline score was calculated as the mean of the scores in the index joint over the 3 days days in the initial pain assessment period and a weekly mean was calculated using the daily pain scores in the index joint within each study week. The change from Baseline was calculated using the difference between each post-baseline weekly mean and the baseline mean score, where negative change indicated an improvement.</description>
        <time_frame>Baseline, Weeks 1, 2, 3, 4, 6, 8, 10, 12, 16, 20, and 24</time_frame>
        <population>ITT analysis set included all randomized participants who received at least 1 dose of intravenous study medication (either tanezumab or matching placebo). Here 'overall number of participants analyzed' signifies participants evaluable for this measure. LOCF method was used to impute missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + Diclofenac</title>
            <description>Placebo matched to tanezumab (RN624 or PF-04383119) intravenous infusion at Baseline, Week 8 and Week 16 along with diclofenac 75 milligram (mg) slow release tablet orally twice daily up to Week 32.</description>
          </group>
          <group group_id="O2">
            <title>Tanezumab 2.5 mg + Diclofenac</title>
            <description>Tanezumab (RN624 or PF-04383119) 2.5 mg intravenous infusion at Baseline, Week 8 and Week 16 along with diclofenac 75 mg slow release tablet orally twice daily up to Week 32.</description>
          </group>
          <group group_id="O3">
            <title>Tanezumab 5 mg + Diclofenac</title>
            <description>Tanezumab (RN624 or PF-04383119) 5 mg intravenous infusion at Baseline, Week 8 and Week 16 along with diclofenac 75 mg slow release tablet orally twice daily up to Week 32.</description>
          </group>
          <group group_id="O4">
            <title>Tanezumab 10 mg + Diclofenac</title>
            <description>Tanezumab (RN624 or PF-04383119) 10 mg intravenous infusion at Baseline, Week 8 and Week 16 along with diclofenac 75 mg slow release tablet orally twice daily up to Week 32.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Average Pain Score in the Index Knee or Hip at Weeks 1, 2, 3, 4, 6, 8, 10, 12, 16, 20, and 24</title>
          <description>Participants were asked to assess index joint (knee/hip) pain during the past 24 hours on an 0-10 point integer scale ranging from 0 (no pain) to 10 (worst possible pain). Baseline score was calculated as the mean of the scores in the index joint over the 3 days days in the initial pain assessment period and a weekly mean was calculated using the daily pain scores in the index joint within each study week. The change from Baseline was calculated using the difference between each post-baseline weekly mean and the baseline mean score, where negative change indicated an improvement.</description>
          <population>ITT analysis set included all randomized participants who received at least 1 dose of intravenous study medication (either tanezumab or matching placebo). Here 'overall number of participants analyzed' signifies participants evaluable for this measure. LOCF method was used to impute missing values.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="142"/>
                <count group_id="O2" value="150"/>
                <count group_id="O3" value="141"/>
                <count group_id="O4" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.31" spread="1.39"/>
                    <measurement group_id="O2" value="6.29" spread="1.30"/>
                    <measurement group_id="O3" value="6.38" spread="1.48"/>
                    <measurement group_id="O4" value="6.34" spread="1.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.55" spread="1.12"/>
                    <measurement group_id="O2" value="-0.74" spread="1.10"/>
                    <measurement group_id="O3" value="-1.22" spread="1.49"/>
                    <measurement group_id="O4" value="-0.96" spread="1.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.95" spread="1.43"/>
                    <measurement group_id="O2" value="-0.91" spread="1.40"/>
                    <measurement group_id="O3" value="-1.28" spread="1.76"/>
                    <measurement group_id="O4" value="-1.03" spread="1.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.19" spread="1.65"/>
                    <measurement group_id="O2" value="-1.19" spread="1.57"/>
                    <measurement group_id="O3" value="-1.40" spread="1.73"/>
                    <measurement group_id="O4" value="-1.08" spread="1.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.28" spread="1.65"/>
                    <measurement group_id="O2" value="-1.45" spread="1.70"/>
                    <measurement group_id="O3" value="-1.77" spread="1.74"/>
                    <measurement group_id="O4" value="-1.44" spread="1.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.38" spread="1.58"/>
                    <measurement group_id="O2" value="-1.57" spread="1.75"/>
                    <measurement group_id="O3" value="-1.88" spread="1.96"/>
                    <measurement group_id="O4" value="-1.69" spread="1.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.41" spread="1.64"/>
                    <measurement group_id="O2" value="-1.62" spread="1.75"/>
                    <measurement group_id="O3" value="-1.84" spread="2.00"/>
                    <measurement group_id="O4" value="-1.80" spread="1.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.41" spread="1.77"/>
                    <measurement group_id="O2" value="-1.79" spread="1.88"/>
                    <measurement group_id="O3" value="-2.09" spread="2.13"/>
                    <measurement group_id="O4" value="-2.06" spread="1.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.49" spread="1.75"/>
                    <measurement group_id="O2" value="-1.91" spread="1.82"/>
                    <measurement group_id="O3" value="-2.06" spread="2.19"/>
                    <measurement group_id="O4" value="-2.06" spread="1.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.53" spread="1.82"/>
                    <measurement group_id="O2" value="-1.87" spread="1.90"/>
                    <measurement group_id="O3" value="-2.07" spread="2.25"/>
                    <measurement group_id="O4" value="-2.15" spread="2.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.61" spread="1.85"/>
                    <measurement group_id="O2" value="-1.95" spread="1.94"/>
                    <measurement group_id="O3" value="-2.19" spread="2.34"/>
                    <measurement group_id="O4" value="-2.15" spread="2.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.65" spread="1.89"/>
                    <measurement group_id="O2" value="-1.84" spread="1.96"/>
                    <measurement group_id="O3" value="-2.07" spread="2.31"/>
                    <measurement group_id="O4" value="-2.03" spread="2.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Stiffness Subscale Score at Weeks 2, 4, 8, 12, 16, and 24</title>
        <description>WOMAC: Self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with OA. WOMAC stiffness subscale is a 2-item questionnaire used to assess the amount of stiffness experienced due to osteoarthritis in index knee or hip during past 48 hours. It is calculated as mean of the scores from 2 individual questions scored on NRS of (no stiffness) to 10 (extreme stiffness), with higher scores indicate higher stiffness. Total score range for WOMAC stiffness subscale score is (no stiffness) to 10 (extreme stiffness), where higher scores indicate higher stiffness. Stiffness is defined as a sensation of decreased ease in movement of knee/hip. Negative change indicated an improvement.</description>
        <time_frame>Baseline, Weeks 2, 4, 8, 12, 16, and 24</time_frame>
        <population>ITT analysis set included all randomized participants who received at least 1 dose of intravenous study medication (either tanezumab or matching placebo). Here 'overall number of participants analyzed' signifies participants evaluable for this measure. LOCF method was used to impute missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + Diclofenac</title>
            <description>Placebo matched to tanezumab (RN624 or PF-04383119) intravenous infusion at Baseline, Week 8 and Week 16 along with diclofenac 75 milligram (mg) slow release tablet orally twice daily up to Week 32.</description>
          </group>
          <group group_id="O2">
            <title>Tanezumab 2.5 mg + Diclofenac</title>
            <description>Tanezumab (RN624 or PF-04383119) 2.5 mg intravenous infusion at Baseline, Week 8 and Week 16 along with diclofenac 75 mg slow release tablet orally twice daily up to Week 32.</description>
          </group>
          <group group_id="O3">
            <title>Tanezumab 5 mg + Diclofenac</title>
            <description>Tanezumab (RN624 or PF-04383119) 5 mg intravenous infusion at Baseline, Week 8 and Week 16 along with diclofenac 75 mg slow release tablet orally twice daily up to Week 32.</description>
          </group>
          <group group_id="O4">
            <title>Tanezumab 10 mg + Diclofenac</title>
            <description>Tanezumab (RN624 or PF-04383119) 10 mg intravenous infusion at Baseline, Week 8 and Week 16 along with diclofenac 75 mg slow release tablet orally twice daily up to Week 32.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Stiffness Subscale Score at Weeks 2, 4, 8, 12, 16, and 24</title>
          <description>WOMAC: Self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with OA. WOMAC stiffness subscale is a 2-item questionnaire used to assess the amount of stiffness experienced due to osteoarthritis in index knee or hip during past 48 hours. It is calculated as mean of the scores from 2 individual questions scored on NRS of (no stiffness) to 10 (extreme stiffness), with higher scores indicate higher stiffness. Total score range for WOMAC stiffness subscale score is (no stiffness) to 10 (extreme stiffness), where higher scores indicate higher stiffness. Stiffness is defined as a sensation of decreased ease in movement of knee/hip. Negative change indicated an improvement.</description>
          <population>ITT analysis set included all randomized participants who received at least 1 dose of intravenous study medication (either tanezumab or matching placebo). Here 'overall number of participants analyzed' signifies participants evaluable for this measure. LOCF method was used to impute missing values.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="156"/>
                <count group_id="O3" value="150"/>
                <count group_id="O4" value="145"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.84" spread="1.78"/>
                    <measurement group_id="O2" value="5.61" spread="1.85"/>
                    <measurement group_id="O3" value="5.51" spread="1.52"/>
                    <measurement group_id="O4" value="5.60" spread="1.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.31" spread="1.75"/>
                    <measurement group_id="O2" value="-1.29" spread="1.82"/>
                    <measurement group_id="O3" value="-1.38" spread="1.77"/>
                    <measurement group_id="O4" value="-1.27" spread="1.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.37" spread="1.83"/>
                    <measurement group_id="O2" value="-1.71" spread="2.14"/>
                    <measurement group_id="O3" value="-2.21" spread="2.07"/>
                    <measurement group_id="O4" value="-2.01" spread="2.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.56" spread="1.89"/>
                    <measurement group_id="O2" value="-1.86" spread="2.07"/>
                    <measurement group_id="O3" value="-2.20" spread="2.18"/>
                    <measurement group_id="O4" value="-2.34" spread="2.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.66" spread="1.94"/>
                    <measurement group_id="O2" value="-2.36" spread="2.16"/>
                    <measurement group_id="O3" value="-2.42" spread="2.27"/>
                    <measurement group_id="O4" value="-2.55" spread="2.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.72" spread="2.11"/>
                    <measurement group_id="O2" value="-2.27" spread="2.33"/>
                    <measurement group_id="O3" value="-2.15" spread="2.23"/>
                    <measurement group_id="O4" value="-2.53" spread="2.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.70" spread="2.17"/>
                    <measurement group_id="O2" value="-2.06" spread="2.35"/>
                    <measurement group_id="O3" value="-2.08" spread="2.43"/>
                    <measurement group_id="O4" value="-2.22" spread="2.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Average Score at Weeks 2, 4, 8, 12, 16, and 24</title>
        <description>WOMAC Index: self-administered, disease-specific 24 item questionnaire which assesses clinically important, participant-relevant symptoms for pain (5 items), stiffness (2 items), and physical function (17 items) in participants with osteoarthritis of the hip and/or knee. WOMAC average score is the mean of the WOMAC pain, physical function and stiffness subscale scores and ranges from 0 to 10, with higher score indicating worse response. Greater reduction in WOMAC average score indicated greater improvement.</description>
        <time_frame>Baseline, Weeks 2, 4, 8, 12, 16, and 24</time_frame>
        <population>ITT analysis set included all randomized participants who received at least 1 dose of intravenous study medication (either tanezumab or matching placebo). Here 'overall number of participants analyzed' signifies participants evaluable for this measure. LOCF method was used to impute missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + Diclofenac</title>
            <description>Placebo matched to tanezumab (RN624 or PF-04383119) intravenous infusion at Baseline, Week 8 and Week 16 along with diclofenac 75 milligram (mg) slow release tablet orally twice daily up to Week 32.</description>
          </group>
          <group group_id="O2">
            <title>Tanezumab 2.5 mg + Diclofenac</title>
            <description>Tanezumab (RN624 or PF-04383119) 2.5 mg intravenous infusion at Baseline, Week 8 and Week 16 along with diclofenac 75 mg slow release tablet orally twice daily up to Week 32.</description>
          </group>
          <group group_id="O3">
            <title>Tanezumab 5 mg + Diclofenac</title>
            <description>Tanezumab (RN624 or PF-04383119) 5 mg intravenous infusion at Baseline, Week 8 and Week 16 along with diclofenac 75 mg slow release tablet orally twice daily up to Week 32.</description>
          </group>
          <group group_id="O4">
            <title>Tanezumab 10 mg + Diclofenac</title>
            <description>Tanezumab (RN624 or PF-04383119) 10 mg intravenous infusion at Baseline, Week 8 and Week 16 along with diclofenac 75 mg slow release tablet orally twice daily up to Week 32.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Average Score at Weeks 2, 4, 8, 12, 16, and 24</title>
          <description>WOMAC Index: self-administered, disease-specific 24 item questionnaire which assesses clinically important, participant-relevant symptoms for pain (5 items), stiffness (2 items), and physical function (17 items) in participants with osteoarthritis of the hip and/or knee. WOMAC average score is the mean of the WOMAC pain, physical function and stiffness subscale scores and ranges from 0 to 10, with higher score indicating worse response. Greater reduction in WOMAC average score indicated greater improvement.</description>
          <population>ITT analysis set included all randomized participants who received at least 1 dose of intravenous study medication (either tanezumab or matching placebo). Here 'overall number of participants analyzed' signifies participants evaluable for this measure. LOCF method was used to impute missing values.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="156"/>
                <count group_id="O3" value="150"/>
                <count group_id="O4" value="145"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.05" spread="1.31"/>
                    <measurement group_id="O2" value="5.75" spread="1.43"/>
                    <measurement group_id="O3" value="5.72" spread="1.19"/>
                    <measurement group_id="O4" value="5.80" spread="1.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.31" spread="1.36"/>
                    <measurement group_id="O2" value="-1.23" spread="1.44"/>
                    <measurement group_id="O3" value="-1.30" spread="1.52"/>
                    <measurement group_id="O4" value="-1.06" spread="1.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.45" spread="1.47"/>
                    <measurement group_id="O2" value="-1.68" spread="1.68"/>
                    <measurement group_id="O3" value="-2.14" spread="1.74"/>
                    <measurement group_id="O4" value="-1.92" spread="1.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.59" spread="1.51"/>
                    <measurement group_id="O2" value="-1.83" spread="1.67"/>
                    <measurement group_id="O3" value="-2.21" spread="1.86"/>
                    <measurement group_id="O4" value="-2.27" spread="1.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.74" spread="1.56"/>
                    <measurement group_id="O2" value="-2.24" spread="1.82"/>
                    <measurement group_id="O3" value="-2.45" spread="1.97"/>
                    <measurement group_id="O4" value="-2.42" spread="1.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.80" spread="1.78"/>
                    <measurement group_id="O2" value="-2.19" spread="1.93"/>
                    <measurement group_id="O3" value="-2.22" spread="1.93"/>
                    <measurement group_id="O4" value="-2.43" spread="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.74" spread="1.83"/>
                    <measurement group_id="O2" value="-2.05" spread="2.06"/>
                    <measurement group_id="O3" value="-2.16" spread="2.16"/>
                    <measurement group_id="O4" value="-2.17" spread="2.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Item: Pain When Walking on a Flat Surface at Weeks 2, 4, 8, 12, 16, and 24</title>
        <description>Participants answered the question: &quot;How much pain have you had when walking on a flat surface?&quot; Participants responded by using an 11-point scale where 0 = no pain and 10 = extreme pain. Where 0 is the best response and negative change indicated an improvement.</description>
        <time_frame>Baseline, Week 2, 4, 8, 12, 16, 24</time_frame>
        <population>ITT analysis set included all randomized participants who received at least 1 dose of intravenous study medication (either tanezumab or matching placebo). Here 'overall number of participants analyzed' signifies participants evaluable for this measure. LOCF method was used to impute missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + Diclofenac</title>
            <description>Placebo matched to tanezumab (RN624 or PF-04383119) intravenous infusion at Baseline, Week 8 and Week 16 along with diclofenac 75 milligram (mg) slow release tablet orally twice daily up to Week 32.</description>
          </group>
          <group group_id="O2">
            <title>Tanezumab 2.5 mg + Diclofenac</title>
            <description>Tanezumab (RN624 or PF-04383119) 2.5 mg intravenous infusion at Baseline, Week 8 and Week 16 along with diclofenac 75 mg slow release tablet orally twice daily up to Week 32.</description>
          </group>
          <group group_id="O3">
            <title>Tanezumab 5 mg + Diclofenac</title>
            <description>Tanezumab (RN624 or PF-04383119) 5 mg intravenous infusion at Baseline, Week 8 and Week 16 along with diclofenac 75 mg slow release tablet orally twice daily up to Week 32.</description>
          </group>
          <group group_id="O4">
            <title>Tanezumab 10 mg + Diclofenac</title>
            <description>Tanezumab (RN624 or PF-04383119) 10 mg intravenous infusion at Baseline, Week 8 and Week 16 along with diclofenac 75 mg slow release tablet orally twice daily up to Week 32.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Item: Pain When Walking on a Flat Surface at Weeks 2, 4, 8, 12, 16, and 24</title>
          <description>Participants answered the question: &quot;How much pain have you had when walking on a flat surface?&quot; Participants responded by using an 11-point scale where 0 = no pain and 10 = extreme pain. Where 0 is the best response and negative change indicated an improvement.</description>
          <population>ITT analysis set included all randomized participants who received at least 1 dose of intravenous study medication (either tanezumab or matching placebo). Here 'overall number of participants analyzed' signifies participants evaluable for this measure. LOCF method was used to impute missing values.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="156"/>
                <count group_id="O3" value="150"/>
                <count group_id="O4" value="145"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.12" spread="1.67"/>
                    <measurement group_id="O2" value="5.91" spread="1.74"/>
                    <measurement group_id="O3" value="5.81" spread="1.54"/>
                    <measurement group_id="O4" value="5.99" spread="1.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.34" spread="1.71"/>
                    <measurement group_id="O2" value="-1.23" spread="1.76"/>
                    <measurement group_id="O3" value="-1.07" spread="1.82"/>
                    <measurement group_id="O4" value="-0.89" spread="1.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.47" spread="1.74"/>
                    <measurement group_id="O2" value="-1.75" spread="2.07"/>
                    <measurement group_id="O3" value="-2.01" spread="1.99"/>
                    <measurement group_id="O4" value="-1.87" spread="1.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.62" spread="1.78"/>
                    <measurement group_id="O2" value="-1.81" spread="1.84"/>
                    <measurement group_id="O3" value="-2.05" spread="2.15"/>
                    <measurement group_id="O4" value="-2.25" spread="2.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.83" spread="1.92"/>
                    <measurement group_id="O2" value="-2.15" spread="1.94"/>
                    <measurement group_id="O3" value="-2.35" spread="2.41"/>
                    <measurement group_id="O4" value="-2.41" spread="2.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.95" spread="2.12"/>
                    <measurement group_id="O2" value="-2.14" spread="1.99"/>
                    <measurement group_id="O3" value="-2.09" spread="2.38"/>
                    <measurement group_id="O4" value="-2.34" spread="2.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.84" spread="2.13"/>
                    <measurement group_id="O2" value="-2.08" spread="2.38"/>
                    <measurement group_id="O3" value="-2.09" spread="2.54"/>
                    <measurement group_id="O4" value="-2.10" spread="2.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Item: Pain When Going Up or Downstairs at Weeks 2, 4, 8, 12, 16, and 24</title>
        <description>Participants answered the question: &quot;How much pain have you had when going up or down the stairs?&quot; Participants responded by using an 11-point scale, where 0 = no pain and 10 = extreme pain. Where 0 is the best response and negative change indicated an improvement.</description>
        <time_frame>Baseline, Weeks 2, 4, 8, 12, 16, and 24</time_frame>
        <population>ITT analysis set included all randomized participants who received at least 1 dose of intravenous study medication (either tanezumab or matching placebo). Here 'overall number of participants analyzed' signifies participants evaluable for this measure. LOCF method was used to impute missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + Diclofenac</title>
            <description>Placebo matched to tanezumab (RN624 or PF-04383119) intravenous infusion at Baseline, Week 8 and Week 16 along with diclofenac 75 milligram (mg) slow release tablet orally twice daily up to Week 32.</description>
          </group>
          <group group_id="O2">
            <title>Tanezumab 2.5 mg + Diclofenac</title>
            <description>Tanezumab (RN624 or PF-04383119) 2.5 mg intravenous infusion at Baseline, Week 8 and Week 16 along with diclofenac 75 mg slow release tablet orally twice daily up to Week 32.</description>
          </group>
          <group group_id="O3">
            <title>Tanezumab 5 mg + Diclofenac</title>
            <description>Tanezumab (RN624 or PF-04383119) 5 mg intravenous infusion at Baseline, Week 8 and Week 16 along with diclofenac 75 mg slow release tablet orally twice daily up to Week 32.</description>
          </group>
          <group group_id="O4">
            <title>Tanezumab 10 mg + Diclofenac</title>
            <description>Tanezumab (RN624 or PF-04383119) 10 mg intravenous infusion at Baseline, Week 8 and Week 16 along with diclofenac 75 mg slow release tablet orally twice daily up to Week 32.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Item: Pain When Going Up or Downstairs at Weeks 2, 4, 8, 12, 16, and 24</title>
          <description>Participants answered the question: &quot;How much pain have you had when going up or down the stairs?&quot; Participants responded by using an 11-point scale, where 0 = no pain and 10 = extreme pain. Where 0 is the best response and negative change indicated an improvement.</description>
          <population>ITT analysis set included all randomized participants who received at least 1 dose of intravenous study medication (either tanezumab or matching placebo). Here 'overall number of participants analyzed' signifies participants evaluable for this measure. LOCF method was used to impute missing values.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="156"/>
                <count group_id="O3" value="150"/>
                <count group_id="O4" value="145"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.24" spread="1.57"/>
                    <measurement group_id="O2" value="7.04" spread="1.65"/>
                    <measurement group_id="O3" value="7.05" spread="1.63"/>
                    <measurement group_id="O4" value="7.06" spread="1.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.38" spread="1.83"/>
                    <measurement group_id="O2" value="-1.49" spread="1.72"/>
                    <measurement group_id="O3" value="-1.55" spread="1.94"/>
                    <measurement group_id="O4" value="-1.21" spread="1.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.58" spread="1.89"/>
                    <measurement group_id="O2" value="-2.10" spread="2.17"/>
                    <measurement group_id="O3" value="-2.39" spread="2.13"/>
                    <measurement group_id="O4" value="-2.10" spread="2.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.78" spread="1.81"/>
                    <measurement group_id="O2" value="-2.15" spread="2.03"/>
                    <measurement group_id="O3" value="-2.51" spread="2.40"/>
                    <measurement group_id="O4" value="-2.64" spread="2.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.03" spread="1.98"/>
                    <measurement group_id="O2" value="-2.54" spread="2.22"/>
                    <measurement group_id="O3" value="-2.86" spread="2.51"/>
                    <measurement group_id="O4" value="-2.77" spread="2.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.00" spread="2.13"/>
                    <measurement group_id="O2" value="-2.54" spread="2.25"/>
                    <measurement group_id="O3" value="-2.53" spread="2.40"/>
                    <measurement group_id="O4" value="-2.79" spread="2.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.95" spread="2.24"/>
                    <measurement group_id="O2" value="-2.44" spread="2.47"/>
                    <measurement group_id="O3" value="-2.53" spread="2.51"/>
                    <measurement group_id="O4" value="-2.56" spread="2.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 36-Item Short-Form Health Survey Version 2 (SF-36v2) Domain Scores at Week 12 and 24</title>
        <description>SF-36v2 was a standardized survey evaluating 8 aspects of functional health and well-being: physical and social functioning, physical and role limitations due to emotional problems, bodily pain, general health, vitality, and mental health. The total score and the score for a section was an average of the individual question scores, which were scaled 0-100. Higher scores reflected better participant status and positive change indicated an improvement.</description>
        <time_frame>Baseline, Week 12, and 24</time_frame>
        <population>ITT analysis set included all randomized participants who received at least 1 dose of intravenous study medication (either tanezumab or matching placebo). Here 'overall number of participants analyzed' signifies participants evaluable for this measure. LOCF method was used to impute missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + Diclofenac</title>
            <description>Placebo matched to tanezumab (RN624 or PF-04383119) intravenous infusion at Baseline, Week 8 and Week 16 along with diclofenac 75 milligram (mg) slow release tablet orally twice daily up to Week 32.</description>
          </group>
          <group group_id="O2">
            <title>Tanezumab 2.5 mg + Diclofenac</title>
            <description>Tanezumab (RN624 or PF-04383119) 2.5 mg intravenous infusion at Baseline, Week 8 and Week 16 along with diclofenac 75 mg slow release tablet orally twice daily up to Week 32.</description>
          </group>
          <group group_id="O3">
            <title>Tanezumab 5 mg + Diclofenac</title>
            <description>Tanezumab (RN624 or PF-04383119) 5 mg intravenous infusion at Baseline, Week 8 and Week 16 along with diclofenac 75 mg slow release tablet orally twice daily up to Week 32.</description>
          </group>
          <group group_id="O4">
            <title>Tanezumab 10 mg + Diclofenac</title>
            <description>Tanezumab (RN624 or PF-04383119) 10 mg intravenous infusion at Baseline, Week 8 and Week 16 along with diclofenac 75 mg slow release tablet orally twice daily up to Week 32.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 36-Item Short-Form Health Survey Version 2 (SF-36v2) Domain Scores at Week 12 and 24</title>
          <description>SF-36v2 was a standardized survey evaluating 8 aspects of functional health and well-being: physical and social functioning, physical and role limitations due to emotional problems, bodily pain, general health, vitality, and mental health. The total score and the score for a section was an average of the individual question scores, which were scaled 0-100. Higher scores reflected better participant status and positive change indicated an improvement.</description>
          <population>ITT analysis set included all randomized participants who received at least 1 dose of intravenous study medication (either tanezumab or matching placebo). Here 'overall number of participants analyzed' signifies participants evaluable for this measure. LOCF method was used to impute missing values.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="156"/>
                <count group_id="O3" value="150"/>
                <count group_id="O4" value="145"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline: General Health</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.37" spread="17.64"/>
                    <measurement group_id="O2" value="49.41" spread="15.67"/>
                    <measurement group_id="O3" value="47.00" spread="15.79"/>
                    <measurement group_id="O4" value="49.31" spread="16.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Physical Function</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.51" spread="18.98"/>
                    <measurement group_id="O2" value="36.22" spread="18.90"/>
                    <measurement group_id="O3" value="34.70" spread="16.56"/>
                    <measurement group_id="O4" value="36.52" spread="18.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Role Physical</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.67" spread="21.79"/>
                    <measurement group_id="O2" value="47.44" spread="20.65"/>
                    <measurement group_id="O3" value="48.50" spread="22.21"/>
                    <measurement group_id="O4" value="47.46" spread="22.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Bodily Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.99" spread="13.77"/>
                    <measurement group_id="O2" value="35.66" spread="12.43"/>
                    <measurement group_id="O3" value="33.95" spread="14.15"/>
                    <measurement group_id="O4" value="35.06" spread="13.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Vitality</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.08" spread="17.73"/>
                    <measurement group_id="O2" value="52.22" spread="16.82"/>
                    <measurement group_id="O3" value="53.00" spread="17.89"/>
                    <measurement group_id="O4" value="51.29" spread="18.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Social Function</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.02" spread="23.59"/>
                    <measurement group_id="O2" value="67.63" spread="23.50"/>
                    <measurement group_id="O3" value="65.83" spread="23.65"/>
                    <measurement group_id="O4" value="66.55" spread="23.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Role Emotional</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.15" spread="26.16"/>
                    <measurement group_id="O2" value="68.96" spread="24.22"/>
                    <measurement group_id="O3" value="68.44" spread="25.86"/>
                    <measurement group_id="O4" value="69.77" spread="24.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Mental Health</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.80" spread="20.39"/>
                    <measurement group_id="O2" value="66.57" spread="17.12"/>
                    <measurement group_id="O3" value="64.63" spread="18.13"/>
                    <measurement group_id="O4" value="65.48" spread="17.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 12: General Health</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.67" spread="16.11"/>
                    <measurement group_id="O2" value="5.29" spread="14.70"/>
                    <measurement group_id="O3" value="6.55" spread="13.94"/>
                    <measurement group_id="O4" value="4.96" spread="16.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 12: Physical Function</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.36" spread="18.33"/>
                    <measurement group_id="O2" value="10.96" spread="20.84"/>
                    <measurement group_id="O3" value="12.83" spread="22.71"/>
                    <measurement group_id="O4" value="9.90" spread="22.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 12: Role Physical</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.61" spread="22.23"/>
                    <measurement group_id="O2" value="8.81" spread="23.59"/>
                    <measurement group_id="O3" value="7.71" spread="23.45"/>
                    <measurement group_id="O4" value="8.49" spread="25.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 12: Bodily Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.76" spread="16.79"/>
                    <measurement group_id="O2" value="12.51" spread="20.98"/>
                    <measurement group_id="O3" value="15.18" spread="21.49"/>
                    <measurement group_id="O4" value="12.76" spread="22.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 12: Vitality</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.80" spread="14.82"/>
                    <measurement group_id="O2" value="4.23" spread="16.17"/>
                    <measurement group_id="O3" value="3.79" spread="18.57"/>
                    <measurement group_id="O4" value="5.34" spread="18.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 12: Social Function</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.02" spread="22.39"/>
                    <measurement group_id="O2" value="6.25" spread="20.55"/>
                    <measurement group_id="O3" value="4.17" spread="22.37"/>
                    <measurement group_id="O4" value="4.22" spread="22.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 12: Role Emotional</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.92" spread="24.98"/>
                    <measurement group_id="O2" value="2.24" spread="24.40"/>
                    <measurement group_id="O3" value="2.17" spread="29.05"/>
                    <measurement group_id="O4" value="-1.26" spread="27.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 12: Mental Health</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.13" spread="15.58"/>
                    <measurement group_id="O2" value="1.55" spread="16.05"/>
                    <measurement group_id="O3" value="2.20" spread="16.18"/>
                    <measurement group_id="O4" value="1.66" spread="16.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 24: General Health</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.41" spread="16.95"/>
                    <measurement group_id="O2" value="4.51" spread="14.94"/>
                    <measurement group_id="O3" value="4.94" spread="15.57"/>
                    <measurement group_id="O4" value="3.08" spread="18.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 24: Physical Function</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.21" spread="19.01"/>
                    <measurement group_id="O2" value="8.78" spread="22.64"/>
                    <measurement group_id="O3" value="10.50" spread="22.86"/>
                    <measurement group_id="O4" value="8.50" spread="23.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 24: Role Physical</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.17" spread="22.95"/>
                    <measurement group_id="O2" value="8.41" spread="22.77"/>
                    <measurement group_id="O3" value="6.96" spread="26.61"/>
                    <measurement group_id="O4" value="5.91" spread="27.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 24: Bodily Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.14" spread="19.41"/>
                    <measurement group_id="O2" value="12.54" spread="21.40"/>
                    <measurement group_id="O3" value="13.27" spread="24.78"/>
                    <measurement group_id="O4" value="11.52" spread="24.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 24: Vitality</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.66" spread="16.11"/>
                    <measurement group_id="O2" value="2.43" spread="17.72"/>
                    <measurement group_id="O3" value="2.58" spread="20.02"/>
                    <measurement group_id="O4" value="2.76" spread="21.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 24: Social Function</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.36" spread="22.85"/>
                    <measurement group_id="O2" value="4.09" spread="24.27"/>
                    <measurement group_id="O3" value="3.67" spread="24.04"/>
                    <measurement group_id="O4" value="1.38" spread="28.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 24: Role Emotional</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.55" spread="25.48"/>
                    <measurement group_id="O2" value="0.69" spread="23.91"/>
                    <measurement group_id="O3" value="-1.33" spread="28.95"/>
                    <measurement group_id="O4" value="-1.95" spread="27.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 24: Mental Health</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.27" spread="16.66"/>
                    <measurement group_id="O2" value="2.06" spread="16.93"/>
                    <measurement group_id="O3" value="1.63" spread="16.10"/>
                    <measurement group_id="O4" value="0.45" spread="18.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 36-Item Short-Form Health Survey Version 2 (SF-36v2) Physical and Mental Component Scores at Week 12 and 24</title>
        <description>SF-36v2: standardized survey evaluating 8 aspects of functional health and wellbeing (physical and social functioning, role limitations due to physical and emotional problems, bodily pain, general health, vitality, mental health). Total score for each aspect were scaled 0-100. Higher scores reflect better participant status and positive change indicated an improvement. For obtaining physical and mental component scores, z-score for each scale=(observed score - mean score for general 1990 United States [US] population)/corresponding standard deviation. The 2 component scores were obtained by multiplying each aspect z-score by physical or mental factor score coefficient (1990 general US population) and summing the eight products. Component scores indicated how many standard deviations higher (in case of positive z-score [better functioning])/lower (in case of negative z-score [worse functioning]) participant's value was relative to the mean of the reference population.</description>
        <time_frame>Baseline, Week 12 and 24</time_frame>
        <population>ITT analysis set included all randomized participants who received at least 1 dose of intravenous study medication (either tanezumab or matching placebo). Here 'overall number of participants analyzed' signifies participants evaluable for this measure. LOCF method was used to impute missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + Diclofenac</title>
            <description>Placebo matched to tanezumab (RN624 or PF-04383119) intravenous infusion at Baseline, Week 8 and Week 16 along with diclofenac 75 milligram (mg) slow release tablet orally twice daily up to Week 32.</description>
          </group>
          <group group_id="O2">
            <title>Tanezumab 2.5 mg + Diclofenac</title>
            <description>Tanezumab (RN624 or PF-04383119) 2.5 mg intravenous infusion at Baseline, Week 8 and Week 16 along with diclofenac 75 mg slow release tablet orally twice daily up to Week 32.</description>
          </group>
          <group group_id="O3">
            <title>Tanezumab 5 mg + Diclofenac</title>
            <description>Tanezumab (RN624 or PF-04383119) 5 mg intravenous infusion at Baseline, Week 8 and Week 16 along with diclofenac 75 mg slow release tablet orally twice daily up to Week 32.</description>
          </group>
          <group group_id="O4">
            <title>Tanezumab 10 mg + Diclofenac</title>
            <description>Tanezumab (RN624 or PF-04383119) 10 mg intravenous infusion at Baseline, Week 8 and Week 16 along with diclofenac 75 mg slow release tablet orally twice daily up to Week 32.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 36-Item Short-Form Health Survey Version 2 (SF-36v2) Physical and Mental Component Scores at Week 12 and 24</title>
          <description>SF-36v2: standardized survey evaluating 8 aspects of functional health and wellbeing (physical and social functioning, role limitations due to physical and emotional problems, bodily pain, general health, vitality, mental health). Total score for each aspect were scaled 0-100. Higher scores reflect better participant status and positive change indicated an improvement. For obtaining physical and mental component scores, z-score for each scale=(observed score - mean score for general 1990 United States [US] population)/corresponding standard deviation. The 2 component scores were obtained by multiplying each aspect z-score by physical or mental factor score coefficient (1990 general US population) and summing the eight products. Component scores indicated how many standard deviations higher (in case of positive z-score [better functioning])/lower (in case of negative z-score [worse functioning]) participant's value was relative to the mean of the reference population.</description>
          <population>ITT analysis set included all randomized participants who received at least 1 dose of intravenous study medication (either tanezumab or matching placebo). Here 'overall number of participants analyzed' signifies participants evaluable for this measure. LOCF method was used to impute missing values.</population>
          <units>z-score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="156"/>
                <count group_id="O3" value="150"/>
                <count group_id="O4" value="145"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline: Physical Component Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.84" spread="0.67"/>
                    <measurement group_id="O2" value="-1.76" spread="0.64"/>
                    <measurement group_id="O3" value="-1.80" spread="0.61"/>
                    <measurement group_id="O4" value="-1.76" spread="0.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Mental Component Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.30" spread="1.16"/>
                    <measurement group_id="O2" value="-0.11" spread="1.05"/>
                    <measurement group_id="O3" value="-0.17" spread="1.09"/>
                    <measurement group_id="O4" value="-0.15" spread="1.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 12: Physical Component Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.35" spread="0.66"/>
                    <measurement group_id="O2" value="0.50" spread="0.76"/>
                    <measurement group_id="O3" value="0.56" spread="0.73"/>
                    <measurement group_id="O4" value="0.51" spread="0.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 12: Mental Component Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08" spread="0.92"/>
                    <measurement group_id="O2" value="0.01" spread="0.90"/>
                    <measurement group_id="O3" value="-0.03" spread="0.96"/>
                    <measurement group_id="O4" value="-0.06" spread="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 24: Physical Component Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.32" spread="0.76"/>
                    <measurement group_id="O2" value="0.45" spread="0.76"/>
                    <measurement group_id="O3" value="0.50" spread="0.83"/>
                    <measurement group_id="O4" value="0.43" spread="0.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 24: Mental Component Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.03" spread="0.94"/>
                    <measurement group_id="O2" value="-0.03" spread="0.98"/>
                    <measurement group_id="O3" value="-0.10" spread="0.94"/>
                    <measurement group_id="O4" value="-0.14" spread="1.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in European Quality of Life - 5 Dimension (EQ-5D) Index Score at Week 24</title>
        <description>EQ-5D was a standardized, participant-administered measure of health outcome. It provides a descriptive profile for 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), using 3 levels (no, moderate, or extreme dysfunction) and a single index value characterizing current health status using a visual analog scale with score ranging from 0 (worst) to 100 (best). EQ-5D summary index was obtained with a formula that weights each level of the dimensions. The index-based score was interpreted along a continuum of 0 (death) to 1 (perfect health). Negative change from baseline represented worsening.</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>ITT analysis set included all randomized participants who received at least 1 dose of intravenous study medication (either tanezumab or matching placebo). Here 'overall number of participants analyzed' signifies participants evaluable for this measure and 'number analyzed' signifies number of participants evaluable for each specified time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + Diclofenac</title>
            <description>Placebo matched to tanezumab (RN624 or PF-04383119) intravenous infusion at Baseline, Week 8 and Week 16 along with diclofenac 75 milligram (mg) slow release tablet orally twice daily up to Week 32.</description>
          </group>
          <group group_id="O2">
            <title>Tanezumab 2.5 mg + Diclofenac</title>
            <description>Tanezumab (RN624 or PF-04383119) 2.5 mg intravenous infusion at Baseline, Week 8 and Week 16 along with diclofenac 75 mg slow release tablet orally twice daily up to Week 32.</description>
          </group>
          <group group_id="O3">
            <title>Tanezumab 5 mg + Diclofenac</title>
            <description>Tanezumab (RN624 or PF-04383119) 5 mg intravenous infusion at Baseline, Week 8 and Week 16 along with diclofenac 75 mg slow release tablet orally twice daily up to Week 32.</description>
          </group>
          <group group_id="O4">
            <title>Tanezumab 10 mg + Diclofenac</title>
            <description>Tanezumab (RN624 or PF-04383119) 10 mg intravenous infusion at Baseline, Week 8 and Week 16 along with diclofenac 75 mg slow release tablet orally twice daily up to Week 32.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in European Quality of Life - 5 Dimension (EQ-5D) Index Score at Week 24</title>
          <description>EQ-5D was a standardized, participant-administered measure of health outcome. It provides a descriptive profile for 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), using 3 levels (no, moderate, or extreme dysfunction) and a single index value characterizing current health status using a visual analog scale with score ranging from 0 (worst) to 100 (best). EQ-5D summary index was obtained with a formula that weights each level of the dimensions. The index-based score was interpreted along a continuum of 0 (death) to 1 (perfect health). Negative change from baseline represented worsening.</description>
          <population>ITT analysis set included all randomized participants who received at least 1 dose of intravenous study medication (either tanezumab or matching placebo). Here 'overall number of participants analyzed' signifies participants evaluable for this measure and 'number analyzed' signifies number of participants evaluable for each specified time point.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="156"/>
                <count group_id="O3" value="150"/>
                <count group_id="O4" value="145"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline: Index Score</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="152"/>
                    <count group_id="O2" value="156"/>
                    <count group_id="O3" value="150"/>
                    <count group_id="O4" value="145"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.45" spread="0.29"/>
                    <measurement group_id="O2" value="0.48" spread="0.25"/>
                    <measurement group_id="O3" value="0.47" spread="0.26"/>
                    <measurement group_id="O4" value="0.47" spread="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 24: Index Score</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="96"/>
                    <count group_id="O2" value="107"/>
                    <count group_id="O3" value="104"/>
                    <count group_id="O4" value="95"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.11" spread="0.35"/>
                    <measurement group_id="O2" value="0.15" spread="0.29"/>
                    <measurement group_id="O3" value="0.14" spread="0.33"/>
                    <measurement group_id="O4" value="0.16" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Change From Baseline in European Quality of Life - 5 Dimension (EQ-5D) Individual Health State Profile at Week 24</title>
        <description>EQ-5D was a standardized, participant-administered measure of health outcome. It provides a descriptive profile for 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), using 3 levels (no, moderate, or extreme dysfunction) and a single index value characterizing current health status using a visual analog scale with score ranging from 0 (worst) to 100 (best). Baseline EQ-5D individual health state profile was determined as number of participants &quot;no dysfunction, moderate or some dysfunction and extreme dysfunction&quot; and change from baseline in EQ-5D individual health state profile was determined as number of participants &quot;improved, no change or worsened&quot;.</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>ITT analysis set included all randomized participants who received at least 1 dose of intravenous study medication (either tanezumab or matching placebo). Here 'overall number of participants analyzed' signifies participants evaluable for this measure. LOCF method was used to impute missing values.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + Diclofenac</title>
            <description>Placebo matched to tanezumab (RN624 or PF-04383119) intravenous infusion at Baseline, Week 8 and Week 16 along with diclofenac 75 milligram (mg) slow release tablet orally twice daily up to Week 32.</description>
          </group>
          <group group_id="O2">
            <title>Tanezumab 2.5 mg + Diclofenac</title>
            <description>Tanezumab (RN624 or PF-04383119) 2.5 mg intravenous infusion at Baseline, Week 8 and Week 16 along with diclofenac 75 mg slow release tablet orally twice daily up to Week 32.</description>
          </group>
          <group group_id="O3">
            <title>Tanezumab 5 mg + Diclofenac</title>
            <description>Tanezumab (RN624 or PF-04383119) 5 mg intravenous infusion at Baseline, Week 8 and Week 16 along with diclofenac 75 mg slow release tablet orally twice daily up to Week 32.</description>
          </group>
          <group group_id="O4">
            <title>Tanezumab 10 mg + Diclofenac</title>
            <description>Tanezumab (RN624 or PF-04383119) 10 mg intravenous infusion at Baseline, Week 8 and Week 16 along with diclofenac 75 mg slow release tablet orally twice daily up to Week 32.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Change From Baseline in European Quality of Life - 5 Dimension (EQ-5D) Individual Health State Profile at Week 24</title>
          <description>EQ-5D was a standardized, participant-administered measure of health outcome. It provides a descriptive profile for 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), using 3 levels (no, moderate, or extreme dysfunction) and a single index value characterizing current health status using a visual analog scale with score ranging from 0 (worst) to 100 (best). Baseline EQ-5D individual health state profile was determined as number of participants &quot;no dysfunction, moderate or some dysfunction and extreme dysfunction&quot; and change from baseline in EQ-5D individual health state profile was determined as number of participants &quot;improved, no change or worsened&quot;.</description>
          <population>ITT analysis set included all randomized participants who received at least 1 dose of intravenous study medication (either tanezumab or matching placebo). Here 'overall number of participants analyzed' signifies participants evaluable for this measure. LOCF method was used to impute missing values.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="156"/>
                <count group_id="O3" value="150"/>
                <count group_id="O4" value="145"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline: Mobility-No Dysfunction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Mobility-Moderate Dysfunction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="143"/>
                    <measurement group_id="O2" value="148"/>
                    <measurement group_id="O3" value="136"/>
                    <measurement group_id="O4" value="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Mobility-Extreme Dysfunction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Self Care-No Dysfunction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="61"/>
                    <measurement group_id="O3" value="53"/>
                    <measurement group_id="O4" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Self Care-Moderate Dysfunction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87"/>
                    <measurement group_id="O2" value="92"/>
                    <measurement group_id="O3" value="96"/>
                    <measurement group_id="O4" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Self Care-Extreme Dysfunction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Usual Activities-No Dysfunction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="20"/>
                    <measurement group_id="O4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Usual Activities-Moderate Dysfunction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116"/>
                    <measurement group_id="O2" value="141"/>
                    <measurement group_id="O3" value="126"/>
                    <measurement group_id="O4" value="123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Usual Activities-Extreme Dysfunction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Pain/Discomfort-No Dysfunction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Pain/Discomfort-Moderate Dysfunction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114"/>
                    <measurement group_id="O2" value="125"/>
                    <measurement group_id="O3" value="115"/>
                    <measurement group_id="O4" value="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Pain/Discomfort-Extreme Dysfunction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="31"/>
                    <measurement group_id="O3" value="33"/>
                    <measurement group_id="O4" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Anxiety/Depression-No Dysfunction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                    <measurement group_id="O2" value="82"/>
                    <measurement group_id="O3" value="70"/>
                    <measurement group_id="O4" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Anxiety/Depression-Moderate Dysfunction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72"/>
                    <measurement group_id="O2" value="72"/>
                    <measurement group_id="O3" value="75"/>
                    <measurement group_id="O4" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline: Anxiety/Depression-Extreme Dysfunction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 24: Mobility-Improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="30"/>
                    <measurement group_id="O4" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 24: Mobility-No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="127"/>
                    <measurement group_id="O2" value="129"/>
                    <measurement group_id="O3" value="114"/>
                    <measurement group_id="O4" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 24: Mobility-Worsened</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 24: Self Care-Improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="33"/>
                    <measurement group_id="O3" value="32"/>
                    <measurement group_id="O4" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 24: Self Care-No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118"/>
                    <measurement group_id="O2" value="112"/>
                    <measurement group_id="O3" value="110"/>
                    <measurement group_id="O4" value="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 24: Self Care-Worsened</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 24: Usual Activities-Improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="31"/>
                    <measurement group_id="O4" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 24: Usual Activities-No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="125"/>
                    <measurement group_id="O2" value="125"/>
                    <measurement group_id="O3" value="106"/>
                    <measurement group_id="O4" value="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 24: Usual Activities-Worsened</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 24: Pain/Discomfort-Improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="34"/>
                    <measurement group_id="O4" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 24: Pain/Discomfort-No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116"/>
                    <measurement group_id="O2" value="125"/>
                    <measurement group_id="O3" value="109"/>
                    <measurement group_id="O4" value="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 24: Pain/Discomfort-Worsened</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 24: Anxiety/Depression-Improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="26"/>
                    <measurement group_id="O3" value="28"/>
                    <measurement group_id="O4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 24: Anxiety/Depression-No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="106"/>
                    <measurement group_id="O2" value="111"/>
                    <measurement group_id="O3" value="109"/>
                    <measurement group_id="O4" value="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 24: Anxiety/Depression-Worsened</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Discontinued Due to Lack of Efficacy</title>
        <description>Number of participants who discontinued due to lack of efficacy were reported.</description>
        <time_frame>Baseline up to end of study (Week 32)</time_frame>
        <population>The ITT analysis set included all randomized participants who received at least 1 dose of intravenous study medication (either tanezumab or matching placebo).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + Diclofenac</title>
            <description>Placebo matched to tanezumab (RN624 or PF-04383119) intravenous infusion at Baseline, Week 8 and Week 16 along with diclofenac 75 milligram (mg) slow release tablet orally twice daily up to Week 32.</description>
          </group>
          <group group_id="O2">
            <title>Tanezumab 2.5 mg + Diclofenac</title>
            <description>Tanezumab (RN624 or PF-04383119) 2.5 mg intravenous infusion at Baseline, Week 8 and Week 16 along with diclofenac 75 mg slow release tablet orally twice daily up to Week 32.</description>
          </group>
          <group group_id="O3">
            <title>Tanezumab 5 mg + Diclofenac</title>
            <description>Tanezumab (RN624 or PF-04383119) 5 mg intravenous infusion at Baseline, Week 8 and Week 16 along with diclofenac 75 mg slow release tablet orally twice daily up to Week 32.</description>
          </group>
          <group group_id="O4">
            <title>Tanezumab 10 mg + Diclofenac</title>
            <description>Tanezumab (RN624 or PF-04383119) 10 mg intravenous infusion at Baseline, Week 8 and Week 16 along with diclofenac 75 mg slow release tablet orally twice daily up to Week 32.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Discontinued Due to Lack of Efficacy</title>
          <description>Number of participants who discontinued due to lack of efficacy were reported.</description>
          <population>The ITT analysis set included all randomized participants who received at least 1 dose of intravenous study medication (either tanezumab or matching placebo).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="157"/>
                <count group_id="O3" value="150"/>
                <count group_id="O4" value="145"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Discontinuation (TTD) Due to Lack of Efficacy</title>
        <description>Median time to discontinuation due to lack of efficacy was estimated using Kaplan-Meier method.</description>
        <time_frame>Baseline up to Week 16 and 24</time_frame>
        <population>The ITT analysis set included all randomized participants who received at least 1 dose of intravenous study medication (either tanezumab or matching placebo).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + Diclofenac</title>
            <description>Placebo matched to tanezumab (RN624 or PF-04383119) intravenous infusion at Baseline, Week 8 and Week 16 along with diclofenac 75 milligram (mg) slow release tablet orally twice daily up to Week 32.</description>
          </group>
          <group group_id="O2">
            <title>Tanezumab 2.5 mg + Diclofenac</title>
            <description>Tanezumab (RN624 or PF-04383119) 2.5 mg intravenous infusion at Baseline, Week 8 and Week 16 along with diclofenac 75 mg slow release tablet orally twice daily up to Week 32.</description>
          </group>
          <group group_id="O3">
            <title>Tanezumab 5 mg + Diclofenac</title>
            <description>Tanezumab (RN624 or PF-04383119) 5 mg intravenous infusion at Baseline, Week 8 and Week 16 along with diclofenac 75 mg slow release tablet orally twice daily up to Week 32.</description>
          </group>
          <group group_id="O4">
            <title>Tanezumab 10 mg + Diclofenac</title>
            <description>Tanezumab (RN624 or PF-04383119) 10 mg intravenous infusion at Baseline, Week 8 and Week 16 along with diclofenac 75 mg slow release tablet orally twice daily up to Week 32.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Discontinuation (TTD) Due to Lack of Efficacy</title>
          <description>Median time to discontinuation due to lack of efficacy was estimated using Kaplan-Meier method.</description>
          <population>The ITT analysis set included all randomized participants who received at least 1 dose of intravenous study medication (either tanezumab or matching placebo).</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="157"/>
                <count group_id="O3" value="150"/>
                <count group_id="O4" value="145"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Median and 95% confidence interval (CI) limits cannot be estimated due to the low number of participants who discontinued due to lack of efficacy.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Median and 95% CI limits cannot be estimated due to the low number of participants who discontinued due to lack of efficacy.</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">Median and 95% CI limits cannot be estimated due to the low number of participants who discontinued due to lack of efficacy.</measurement>
                    <measurement group_id="O4" value="NA" lower_limit="NA" upper_limit="NA">Median and 95% CI limits cannot be estimated due to the low number of participants who discontinued due to lack of efficacy.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Median and 95% CI limits cannot be estimated due to the low number of participants who discontinued due to lack of efficacy.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Median and 95% CI limits cannot be estimated due to the low number of participants who discontinued due to lack of efficacy.</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">Median and 95% CI limits cannot be estimated due to the low number of participants who discontinued due to lack of efficacy.</measurement>
                    <measurement group_id="O4" value="NA" lower_limit="NA" upper_limit="NA">Median and 95% CI limits cannot be estimated due to the low number of participants who discontinued due to lack of efficacy.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)</title>
        <description>An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 112 days after last dose that were absent before treatment or that worsened relative to pretreatment state. AEs included SAEs as well as non-serious AEs which occurred during the trial.</description>
        <time_frame>Baseline up to 112 days after last intravenous dose (up to Week 32)</time_frame>
        <population>The ITT analysis set included all randomized participants who received at least 1 dose of intravenous study medication (either tanezumab or matching placebo).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + Diclofenac</title>
            <description>Placebo matched to tanezumab (RN624 or PF-04383119) intravenous infusion at Baseline, Week 8 and Week 16 along with diclofenac 75 milligram (mg) slow release tablet orally twice daily up to Week 32.</description>
          </group>
          <group group_id="O2">
            <title>Tanezumab 2.5 mg + Diclofenac</title>
            <description>Tanezumab (RN624 or PF-04383119) 2.5 mg intravenous infusion at Baseline, Week 8 and Week 16 along with diclofenac 75 mg slow release tablet orally twice daily up to Week 32.</description>
          </group>
          <group group_id="O3">
            <title>Tanezumab 5 mg + Diclofenac</title>
            <description>Tanezumab (RN624 or PF-04383119) 5 mg intravenous infusion at Baseline, Week 8 and Week 16 along with diclofenac 75 mg slow release tablet orally twice daily up to Week 32.</description>
          </group>
          <group group_id="O4">
            <title>Tanezumab 10 mg + Diclofenac</title>
            <description>Tanezumab (RN624 or PF-04383119) 10 mg intravenous infusion at Baseline, Week 8 and Week 16 along with diclofenac 75 mg slow release tablet orally twice daily up to Week 32.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)</title>
          <description>An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 112 days after last dose that were absent before treatment or that worsened relative to pretreatment state. AEs included SAEs as well as non-serious AEs which occurred during the trial.</description>
          <population>The ITT analysis set included all randomized participants who received at least 1 dose of intravenous study medication (either tanezumab or matching placebo).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="157"/>
                <count group_id="O3" value="150"/>
                <count group_id="O4" value="145"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="71"/>
                    <measurement group_id="O3" value="73"/>
                    <measurement group_id="O4" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Intravenous Doses of Study Medication</title>
        <description>Number of participants were reported based on the maximum number of intravenous (IV) doses of either tanezumab or placebo received.</description>
        <time_frame>Day 1 up to Week 16</time_frame>
        <population>The ITT analysis set included all randomized participants who received at least 1 dose of intravenous study medication (either tanezumab or matching placebo).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo + Diclofenac</title>
            <description>Placebo matched to tanezumab (RN624 or PF-04383119) intravenous infusion at Baseline, Week 8 and Week 16 along with diclofenac 75 milligram (mg) slow release tablet orally twice daily up to Week 32.</description>
          </group>
          <group group_id="O2">
            <title>Tanezumab 2.5 mg + Diclofenac</title>
            <description>Tanezumab (RN624 or PF-04383119) 2.5 mg intravenous infusion at Baseline, Week 8 and Week 16 along with diclofenac 75 mg slow release tablet orally twice daily up to Week 32.</description>
          </group>
          <group group_id="O3">
            <title>Tanezumab 5 mg + Diclofenac</title>
            <description>Tanezumab (RN624 or PF-04383119) 5 mg intravenous infusion at Baseline, Week 8 and Week 16 along with diclofenac 75 mg slow release tablet orally twice daily up to Week 32.</description>
          </group>
          <group group_id="O4">
            <title>Tanezumab 10 mg + Diclofenac</title>
            <description>Tanezumab (RN624 or PF-04383119) 10 mg intravenous infusion at Baseline, Week 8 and Week 16 along with diclofenac 75 mg slow release tablet orally twice daily up to Week 32.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Intravenous Doses of Study Medication</title>
          <description>Number of participants were reported based on the maximum number of intravenous (IV) doses of either tanezumab or placebo received.</description>
          <population>The ITT analysis set included all randomized participants who received at least 1 dose of intravenous study medication (either tanezumab or matching placebo).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="157"/>
                <count group_id="O3" value="150"/>
                <count group_id="O4" value="145"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of IV Doses: 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of IV Doses: 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="34"/>
                    <measurement group_id="O3" value="26"/>
                    <measurement group_id="O4" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of IV Doses: 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="114"/>
                    <measurement group_id="O3" value="109"/>
                    <measurement group_id="O4" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Cases of osteonecrosis (ON) reported in this and other studies of this program, conducted up to 2010 were adjudicated post-hoc by an expert committee (2010-2012). Few of these events (2 of 87 reported ON cases), were confirmed as ON by the committee. Source: https://doi.org/10.1002/art.39492.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo + Diclofenac</title>
          <description>Placebo matched to tanezumab (RN624 or PF-04383119) intravenous infusion at Baseline, Week 8 and Week 16 along with diclofenac 75 milligram (mg) slow release tablet orally twice daily up to Week 32.</description>
        </group>
        <group group_id="E2">
          <title>Tanezumab 2.5 mg + Diclofenac</title>
          <description>Tanezumab (RN624 or PF-04383119) 2.5 mg intravenous infusion at Baseline, Week 8 and Week 16 along with diclofenac 75 mg slow release tablet orally twice daily up to Week 32.</description>
        </group>
        <group group_id="E3">
          <title>Tanezumab 5 mg + Diclofenac</title>
          <description>Tanezumab (RN624 or PF-04383119) 5 mg intravenous infusion at Baseline, Week 8 and Week 16 along with diclofenac 75 mg slow release tablet orally twice daily up to Week 32.</description>
        </group>
        <group group_id="E4">
          <title>Tanezumab 10 mg + Diclofenac</title>
          <description>Tanezumab (RN624 or PF-04383119) 10 mg intravenous infusion at Baseline, Week 8 and Week 16 along with diclofenac 75 mg slow release tablet orally twice daily up to Week 32.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="150"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="145"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="145"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Benign familial pemphigus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
              </event>
              <event>
                <sub_title>Abdominal rigidity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="145"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="145"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
              </event>
              <event>
                <sub_title>Spinal column injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="150"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="145"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="145"/>
              </event>
              <event>
                <sub_title>Pathological fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
              </event>
              <event>
                <sub_title>Synovial cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="145"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Brain neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
              </event>
              <event>
                <sub_title>Cholesteatoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
              </event>
              <event>
                <sub_title>Metastases to bone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Demyelinating polyneuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
              </event>
              <event>
                <sub_title>Radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="145"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="145"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="145"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA 13.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="48" subjects_at_risk="150"/>
                <counts group_id="E4" subjects_affected="46" subjects_at_risk="145"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="150"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="145"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="150"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="145"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="150"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="145"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="145"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="150"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="145"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="150"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="145"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="150"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="145"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="150"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="145"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="150"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="145"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="150"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="145"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="150"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="145"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="150"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="145"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="150"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="145"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="152"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="150"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="145"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Due to United States Food and Drug Administration (FDA) imposed clinical hold, further study drug dosing was stopped prematurely and study was terminated.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

